Thr308

Site Information
kDGAtMKtFCGtPEy SwissProt Entrez-Gene
Blast this site against: NCBI SwissProt PDB
Site Group ID: 447856
Available spectra: 1 CST

In vivo Characterization
Methods used to characterize site in vivo:	[32P] bio-synthetic labeling ( 118 , 257 , 266 , 296 , 316 , 322 , 343 , 369 ) , flow cytometry ( 288 ) , immunoassay ( 132 , 137 ) , immunoprecipitation ( 21 , 23 , 35 , 46 , 51 , 57 , 71 , 95 , 98 , 105 , 113 , 116 , 118 , 123 , 135 , 151 , 154 , 167 , 180 , 196 , 355 ) , mass spectrometry ( 9 , 34 , 41 , 71 , 82 , 83 , 84 , 97 , 102 , 107 , 108 , 124 , 125 , 126 , 127 , 163 , 164 , 165 , 168 , 172 , 182 , 183 , 214 ) , mass spectrometry (in vitro) ( 118 ) , microscopy-colocalization with upstream kinase ( 326 ) , mutation of modification site ( 5 , 6 , 9 , 20 , 35 , 71 , 74 , 80 , 91 , 118 , 178 , 180 , 195 , 205 , 213 , 216 , 230 , 257 , 268 , 276 , 290 , 296 , 322 , 326 , 331 , 348 , 353 , 358 , 367 , 369 ) , peptide sequencing ( 32 , 370 ) , phospho-antibody ( 3 , 4 , 5 , 6 , 7 , 8 , 9 , 10 , 11 , 12 , 13 , 14 , 16 , 17 , 18 , 19 , 20 , 21 , 22 , 23 , 24 , 25 , 26 , 27 , 28 , 29 , 30 , 31 , 33 , 35 , 36 , 37 , 38 , 39 , 40 , 41 , 43 , 44 , 45 , 46 , 48 , 49 , 50 , 51 , 53 , 54 , 55 , 56 , 57 , 60 , 61 , 62 , 63 , 65 , 67 , 68 , 69 , 70 , 71 , 72 , 73 , 74 , 75 , 76 , 78 , 79 , 81 , 86 , 89 , 92 , 95 , 96 , 98 , 99 , 101 , 103 , 105 , 106 , 109 , 110 , 111 , 112 , 113 , 114 , 116 , 117 , 118 , 119 , 120 , 121 , 122 , 123 , 129 , 130 , 131 , 132 , 133 , 134 , 135 , 136 , 137 , 138 , 139 , 140 , 141 , 142 , 143 , 144 , 145 , 146 , 148 , 149 , 150 , 151 , 152 , 153 , 154 , 155 , 156 , 157 , 159 , 160 , 161 , 162 , 166 , 167 , 169 , 171 , 173 , 174 , 175 , 176 , 177 , 178 , 179 , 181 , 184 , 185 , 186 , 187 , 190 , 191 , 192 , 193 , 194 , 195 , 196 , 197 , 199 , 200 , 201 , 202 , 203 , 204 , 205 , 206 , 207 , 208 , 210 , 211 , 212 , 213 , 216 , 218 , 219 , 220 , 221 , 223 , 224 , 225 , 226 , 228 , 229 , 230 , 231 , 232 , 233 , 234 , 236 , 237 , 238 , 239 , 240 , 241 , 242 , 243 , 244 , 245 , 246 , 248 , 249 , 250 , 251 , 252 , 253 , 255 , 256 , 257 , 258 , 259 , 260 , 261 , 262 , 263 , 264 , 265 , 266 , 267 , 268 , 269 , 270 , 271 , 272 , 273 , 274 , 275 , 276 , 277 , 279 , 280 , 281 , 282 , 283 , 284 , 285 , 286 , 287 , 288 , 289 , 290 , 291 , 292 , 293 , 294 , 295 , 296 , 297 , 298 , 299 , 300 , 301 , 302 , 303 , 304 , 305 , 306 , 307 , 308 , 309 , 310 , 311 , 312 , 313 , 314 , 315 , 316 , 318 , 319 , 321 , 322 , 323 , 324 , 325 , 326 , 327 , 328 , 329 , 330 , 331 , 332 , 333 , 334 , 335 , 336 , 337 , 338 , 339 , 340 , 341 , 342 , 343 , 344 , 345 , 346 , 347 , 349 , 350 , 351 , 352 , 353 , 355 , 356 , 357 , 358 , 359 , 360 , 361 , 362 , 364 , 365 , 371 , 372 ) , phosphoamino acid analysis ( 158 , 369 ) , phosphopeptide mapping ( 322 , 369 ) , western blotting ( 3 , 4 , 5 , 6 , 7 , 8 , 9 , 10 , 11 , 12 , 13 , 14 , 17 , 18 , 19 , 20 , 21 , 22 , 23 , 25 , 26 , 27 , 28 , 29 , 30 , 31 , 32 , 33 , 35 , 36 , 38 , 40 , 41 , 43 , 44 , 45 , 46 , 48 , 49 , 50 , 51 , 53 , 54 , 55 , 56 , 57 , 60 , 61 , 62 , 63 , 65 , 67 , 68 , 69 , 70 , 71 , 73 , 74 , 75 , 76 , 78 , 79 , 81 , 86 , 89 , 91 , 92 , 93 , 95 , 96 , 98 , 99 , 101 , 103 , 105 , 106 , 109 , 110 , 111 , 112 , 113 , 114 , 116 , 117 , 118 , 119 , 120 , 121 , 122 , 123 , 129 , 130 , 131 , 132 , 133 , 134 , 135 , 136 , 138 , 139 , 140 , 141 , 142 , 143 , 144 , 145 , 146 , 148 , 149 , 150 , 151 , 152 , 153 , 154 , 155 , 156 , 157 , 158 , 159 , 160 , 161 , 162 , 166 , 167 , 169 , 171 , 173 , 174 , 175 , 176 , 177 , 178 , 179 , 180 , 181 , 184 , 185 , 186 , 187 , 190 , 191 , 192 , 193 , 194 , 195 , 196 , 197 , 199 , 200 , 201 , 202 , 203 , 204 , 205 , 206 , 207 , 208 , 210 , 211 , 212 , 213 , 216 , 218 , 219 , 220 , 221 , 223 , 224 , 225 , 226 , 228 , 229 , 230 , 231 , 232 , 233 , 234 , 237 , 238 , 239 , 240 , 241 , 242 , 243 , 244 , 245 , 246 , 250 , 251 , 252 , 253 , 255 , 259 , 265 , 267 , 269 , 271 , 272 , 273 , 275 , 277 , 279 , 280 , 282 , 283 , 285 , 287 , 289 , 293 , 295 , 296 , 298 , 299 , 302 , 303 , 304 , 307 , 308 , 310 , 313 , 315 , 321 , 322 , 324 , 326 , 327 , 328 , 329 , 331 , 332 , 333 , 335 , 338 , 342 , 351 , 352 , 353 , 355 , 356 , 357 , 358 , 359 , 360 , 361 , 362 , 364 , 365 , 370 , 371 , 372 )
Disease tissue studied:	adrenal cancer ( 252 ) , pheochromocytoma ( 252 ) , bone cancer ( 81 , 101 , 135 , 159 , 173 , 187 , 190 , 210 , 233 , 248 , 277 , 321 ) , Ewing's sarcoma ( 68 , 210 ) , osteosarcoma ( 248 ) , brain cancer ( 41 , 59 , 129 , 143 , 156 , 173 , 184 , 234 , 239 , 251 , 266 , 357 , 372 ) , astrocytoma ( 266 ) , glioblastoma ( 41 , 59 , 129 , 143 , 173 , 234 , 239 , 251 , 357 ) , glioblastoma multiforme ( 71 , 129 , 184 ) , glioma ( 41 , 59 , 71 , 129 , 143 , 173 , 184 , 234 , 239 , 251 , 357 ) , Schwannoma ( 156 , 372 ) , breast cancer ( 5 , 14 , 21 , 35 , 37 , 49 , 53 , 62 , 71 , 73 , 74 , 89 , 106 , 111 , 113 , 118 , 134 , 138 , 140 , 142 , 143 , 146 , 159 , 167 , 173 , 174 , 186 , 190 , 194 , 200 , 202 , 205 , 206 , 249 , 267 , 269 , 272 , 303 , 327 ) , breast adenocarcinoma ( 74 , 89 , 113 , 159 , 190 ) , HER2 positive breast cancer ( 34 ) , luminal A breast cancer ( 34 ) , luminal B breast cancer ( 34 ) , breast cancer, triple negative ( 34 , 62 , 74 , 89 , 113 , 190 ) , cervical cancer ( 134 , 282 , 298 ) , cervical squamous cell carcinoma ( 298 ) , chondrosarcoma ( 248 ) , colorectal cancer ( 32 , 37 , 72 , 86 , 110 , 118 , 134 , 135 , 140 , 160 , 169 , 192 , 328 , 333 ) , colorectal carcinoma ( 32 , 37 , 72 , 86 , 110 , 118 , 134 , 135 , 140 , 160 , 169 , 192 , 328 , 333 ) , endometrial cancer ( 4 , 145 ) , endometrial adenocarcinoma ( 4 , 145 ) , liposarcoma ( 248 ) , gastric cancer ( 33 , 163 , 164 , 273 ) , gastric carcinoma ( 33 , 163 , 164 , 273 ) , gestational cancer ( 141 ) , gestational trophoblastic choriocarcinoma ( 141 ) , kidney cancer ( 91 , 225 , 255 ) , leukemia ( 8 , 25 , 28 , 31 , 61 , 249 , 359 , 360 ) , acute myelogenous leukemia ( 25 , 28 , 31 , 249 , 359 ) , acute erythroid leukemias, including erythroleukemia (M6a) and very rare pure erythroid leukemia (M6b) ( 249 , 360 ) , chronic lymphocytic leukemia ( 8 ) , chronic myelogenous leukemia ( 25 ) , T cell leukemia ( 8 ) , liver cancer ( 47 , 50 , 51 , 57 , 154 , 207 , 237 , 271 ) , liver adenocarcinoma ( 50 ) , hepatocellular carcinoma ( 29 , 47 , 57 , 135 , 154 ) , lung cancer ( 11 , 16 , 19 , 39 , 82 , 83 , 84 , 109 , 118 , 135 , 138 , 165 , 173 , 192 , 293 , 347 ) , non-small cell lung cancer ( 11 , 16 , 19 , 22 , 39 , 82 , 84 , 118 , 135 , 165 , 347 ) , non-small cell lung adenocarcinoma ( 11 , 16 , 19 , 39 , 82 , 83 , 84 , 135 , 165 ) , non-small cell large cell lung carcinoma ( 16 , 19 , 84 ) , non-small cell squamous cell lung carcinoma ( 83 , 165 ) , lymphoma ( 20 , 25 , 67 , 78 , 121 , 175 , 244 , 249 , 287 , 313 ) , B cell lymphoma ( 6 , 20 ) , Burkitt's lymphoma ( 287 ) , non-Hodgkin's lymphoma ( 20 ) , mantle cell lymphoma ( 20 ) , PEL ( 67 , 121 ) , T cell lymphoma ( 244 ) , malignant fibrous histiocytoma ( 248 ) , neuroblastoma ( 123 , 133 , 196 , 234 , 240 ) , ovarian cancer ( 23 , 36 , 134 , 140 , 143 , 153 , 156 , 162 , 218 , 303 , 327 ) , ovarian epithelial carcinoma ( 218 ) , pancreatic cancer ( 12 , 22 , 38 , 43 , 95 , 146 , 192 , 275 ) , pancreatic carcinoma ( 12 , 38 , 43 , 95 , 146 , 192 , 275 ) , pancreatic islet cell cancer ( 22 ) , multiple myeloma ( 10 ) , prostate cancer ( 9 , 51 , 78 , 98 , 99 , 105 , 120 , 134 , 140 , 143 , 150 , 176 , 190 , 191 , 204 , 206 , 242 , 245 , 253 , 333 , 358 , 361 ) , Kaposi's sarcoma ( 121 ) , melanoma skin cancer ( 177 , 205 ) , fibrosarcoma of soft tissue ( 60 , 333 ) , leiomyosarcoma ( 145 , 248 ) , rhabdomyosarcoma ( 210 , 219 , 248 , 307 ) , type 2 diabetes ( 139 )
Relevant cell line - cell type - tissue:	'3T3-L1, differentiated' (adipocyte) ( 74 ) , 'brain, hippocampus' ( 161 ) , 'macrophage, alveolar'-lung ( 350 ) , 'muscle, skeletal' ( 75 , 79 , 136 , 139 , 144 , 203 , 219 , 260 , 261 , 265 , 271 , 283 ) , 'muscle, smooth' ( 283 ) , 'neuron, dorsal root ganglion'-brain ( 289 ) , 'stem, embryonic' ( 103 , 155 ) , 'stem, mesenchymal' ( 13 ) , 1-LN (prostate cell) ( 98 ) , 22Rv1 (prostate cell) ( 204 ) , 293 (epithelial) [IRS1 (human)] ( 223 ) , 293 (epithelial) ( 46 , 73 , 93 , 95 , 117 , 119 , 150 , 151 , 157 , 171 , 173 , 181 , 184 , 193 , 199 , 213 , 216 , 230 , 232 , 243 , 252 , 256 , 257 , 258 , 270 , 272 , 280 , 290 , 305 , 310 , 315 , 326 , 329 , 330 , 341 , 344 , 349 , 351 , 364 , 370 ) , 293E (epithelial) ( 110 , 321 ) , 3T3 (fibroblast) [SHP-2 (mouse), homozygous knockout] ( 296 , 314 , 324 , 337 ) , 3T3 (fibroblast) ( 51 , 118 , 197 , 212 , 216 , 257 , 362 , 367 ) , 661W ( 152 ) , 786-O (renal) ( 91 ) , A2780 (ovarian) ( 134 , 143 , 218 ) , A375 (melanocyte) ( 177 ) , A431 (epithelial) ( 221 , 280 ) , A549 (pulmonary) ( 11 , 16 , 19 , 109 , 135 , 173 , 192 , 274 , 293 ) , A673 (muscle cell) ( 68 ) , adipocyte ( 371 ) , adipocyte-adipose tissue ( 30 ) , adipose tissue ( 45 ) , AGS (gastric) ( 33 ) , AML10 (myeloid) ( 31 ) , AML11 (myeloid) ( 31 ) , AN3-CA (endometrial) ( 145 ) , aorta ( 338 ) , artery-heart ( 246 ) , Aspc1 (pancreatic) ( 43 ) , BAEC (endothelial) ( 199 , 243 , 335 ) , BaF3 ('B lymphocyte, precursor') ( 28 ) , BC3 (B lymphocyte) ( 67 ) , BEAS-2B (epithelial) ( 40 ) , Ben-Men-1 ( 372 ) , BeWo31 ( 185 ) , BeWo ( 185 ) , bile-duct cell-bile-ducts ( 300 ) , Bon1 (pancreatic) ( 22 ) , BPH-1 (epithelial) ( 150 ) , brain ( 234 ) , breast ( 34 ) , breast cell-breast ( 292 ) , BT-474 (breast cell) ( 37 , 89 , 134 , 138 , 146 , 269 , 281 ) , BT-549 (breast cell) ( 62 , 89 ) , BTIC-12 (glial) ( 59 ) , BTIC-48 (glial) ( 59 ) , BxPC-3 (pancreatic) ( 146 ) , C2C12 (myoblast) [SPRY2 (human), transfection] ( 259 ) , C2C12 (myoblast) ( 259 , 283 , 307 ) , C33-A (cervical) ( 134 , 282 ) , C4-2 (prostate cell) ( 176 ) , Calu-1 (squamous) ( 135 ) , Calu-3 (pulmonary) ( 82 ) , Capan1 (pancreatic) ( 38 ) , CCLP1 (hepatic) ( 300 ) , CD18/HPAF (pancreatic) ( 38 ) , CH27 (squamous) ( 337 ) , CHO (fibroblast) [EphB1 (human), transfection] ( 314 ) , CHO (fibroblast) [EPOR (human)] ( 230 ) , CHO (fibroblast) [INSR (human), transfection] ( 353 ) , CHO (fibroblast) ( 26 , 257 , 285 ) , CHO-K1 (fibroblast) ( 74 ) , COS (fibroblast) ( 197 , 200 , 289 , 296 , 322 , 333 , 341 , 345 , 349 , 355 , 365 , 369 ) , COS7 (fibroblast) ( 144 ) , CTL-EN (T lymphocyte) ( 302 ) , DF1 (fibroblast) ( 233 ) , DLBCL (B lymphocyte) ( 6 ) , DLD1 (intestinal) ( 135 , 169 , 263 ) , DM4 (melanocyte) ( 177 ) , DU 145 (prostate cell) ( 98 , 221 , 361 ) , EA.hy 926 (endothelial) ( 340 ) , embryo ( 233 ) , endothelial-vein ( 348 ) , epithelial-lens ( 148 ) , erythroblast ( 359 ) , ES (stem) ( 252 ) , fibroblast-embryo ( 93 , 178 ) , fibroblast-foreskin ( 71 ) , FL5.12 (lymphoid) ( 212 ) , GI-101A (breast cell) ( 303 , 327 ) , glial-brain ( 41 ) , GM00637 (lymphoblast) ( 276 ) , GM08391 (fibroblast) ( 276 ) , GM09607 (fibroblast) ( 276 ) , GRANTA-519 (B lymphocyte) ( 20 ) , H2009 (pulmonary) ( 63 ) , HaCaT (keratinocyte) ( 27 , 158 , 312 , 346 ) , HAEC (endothelial) ( 208 , 338 ) , HAK-1A (hepatic) ( 29 ) , HAK-1B (hepatic) ( 29 ) , HBL-100 (breast cell) ( 89 ) , HCC (hepatic) ( 135 ) , HCC1428 (breast cell) ( 14 ) , HCC15 (pulmonary) ( 83 ) , HCC1500 (breast cell) ( 14 ) , HCC44 (pulmonary) ( 135 ) , HCC78 (pulmonary) ( 84 ) , HCC827 (pulmonary) ( 82 ) , HCCLM3 (hepatic) ( 47 ) , HCN-2 ('neuron, cortical') ( 179 ) , HCT116 (intestinal) ( 32 , 37 , 86 , 118 , 134 , 135 , 169 , 192 , 263 ) , HCT15 (intestinal) ( 72 ) , heart ( 144 , 159 ) , HEC-50B (endometrial) ( 145 ) , HEI-193 (Schwann) ( 156 , 372 ) , HEK293T (epithelial) ( 24 , 35 , 55 , 80 , 112 , 122 , 135 , 144 , 180 , 195 , 226 , 268 , 269 , 274 , 333 , 334 ) , HeLa (cervical) ( 18 , 51 , 69 , 71 , 74 , 101 , 116 , 118 , 119 , 130 , 131 , 132 , 144 , 166 , 182 , 183 , 221 , 228 , 230 , 241 , 274 , 280 , 297 , 304 ) , hematopoietic progenitor-bone marrow ( 236 ) , Hep 3B2.1-7 (hepatic) ( 300 ) , hepatocyte ( 93 ) , hepatocyte-liver ( 5 , 96 , 299 ) , HepG2 (hepatic) ( 51 , 207 , 237 , 261 , 271 ) , HEY (ovarian) ( 303 , 327 ) , HGC-27 (gastric) ( 33 ) , HL60 (myeloid) ( 25 , 61 , 309 , 316 , 343 ) , HLMVECs ( 70 ) , HPB-ALL (T lymphocyte) ( 313 ) , HS294T (melanocyte) ( 177 ) , HT-29 (intestinal) ( 110 , 140 , 268 , 274 , 311 , 328 ) , HT1080 (fibroblast) ( 60 , 290 , 333 ) , hTERT-RPE1 (epithelial) ( 101 ) , HuCCT1 (hepatic) ( 300 ) , HUES-1 ('stem, embryonic') ( 17 ) , HUES-7 ('stem, embryonic') ( 17 ) , HUES-9 ('stem, embryonic') ( 17 ) , Huh7 (hepatic) ( 154 , 207 ) , HUT-78 (T lymphocyte) ( 244 ) , HUVEC (endothelial) ( 48 , 146 , 193 , 285 , 294 , 318 , 331 , 343 , 345 ) , IGROV1 (ovarian) ( 162 ) , IMR32 (neural crest) ( 234 ) , Ishikawa (endometrial) ( 145 ) , JB (epithelial) ( 295 ) , JEG-3 (uterine) ( 141 ) , JEKO-1 (B lymphocyte) ( 20 ) , Jurkat (T lymphocyte) ( 8 , 102 , 124 , 125 , 126 , 127 , 168 , 172 , 214 , 244 , 264 , 286 , 288 , 313 , 337 ) , K562 (erythroid) ( 25 ) , KB (squamous) ( 298 ) , KELLY (neural crest) ( 234 ) , keratinocyte ( 5 ) , KG-1 (myeloid) ( 249 ) , kidney [KLK1 (human)] ( 225 ) , KLE (endometrial) ( 4 , 145 ) , KPL-1 (breast cell) ( 134 ) , L3.6p1 (pancreatic) ( 38 ) , L6 (myoblast) ( 79 , 223 , 260 , 370 ) , LAN-1 (neural crest) ( 196 ) , leukocyte-blood ( 80 ) , liver ( 7 , 144 , 271 ) , LN-Z308 (glial) ( 239 ) , LN229 (glial) ( 129 ) , LNCaP (prostate cell) ( 99 , 143 , 190 , 204 , 242 , 245 , 358 , 361 ) , LOU-NH91 (squamous) ( 83 ) , LS-513 (intestinal) ( 134 ) , lung ( 82 , 83 , 84 , 159 ) , mammary gland ( 336 ) , MCF-10A (breast cell) [GAB2 (human), transfection] ( 200 ) , MCF-10A (breast cell) ( 73 , 140 , 202 , 327 ) , MCF-7 (breast cell) [CYP19A1 (human)] ( 267 ) , MCF-7 (breast cell) ( 14 , 21 , 71 , 73 , 89 , 106 , 134 , 167 , 173 , 190 , 194 , 205 , 206 , 221 , 249 , 272 ) , MDA-MB-231 (breast cell) ( 5 , 35 , 49 , 53 , 89 , 113 , 118 , 134 , 140 , 142 , 143 , 174 , 186 , 194 , 206 ) , MDA-MB-361 (breast cell) ( 89 , 159 ) , MDA-MB-435 (breast cell) ( 89 , 111 ) , MDA-MB-453 (breast cell) ( 89 ) , MDA-MB-468 (breast cell) ( 74 , 89 , 113 , 190 ) , MEF (fibroblast) ( 46 , 51 , 71 , 110 , 118 , 131 , 135 , 144 , 171 , 180 ) , MEF (fibroblast) [Etk (human), heterozygous knockout] ( 92 ) , MEF (fibroblast) [HRas (human)] ( 250 ) , MEF (fibroblast) [IGF1R (mouse)] ( 303 ) , MEF (fibroblast) [p70S6K (mouse), homozygous knockout] ( 155 ) , MEF (fibroblast) [TSC22D2 (human)] ( 221 ) , MEL624 (melanocyte) ( 177 ) , mesangial ( 279 ) , MeWo (melanocyte) ( 177 ) , MHCC97-L (hepatic) ( 47 ) , MIA PaCa (pancreatic) ( 221 ) , MIA PaCa-2 (pancreatic) ( 192 ) , MKN-45 (gastric) ( 163 , 164 , 273 ) , MOLT-4 (T lymphocyte) ( 244 ) , mononuclear ( 238 ) , mononuclear-blood ( 8 ) , MSN (neuron) ( 291 ) , muscle ( 262 ) , MV4-11 (macrophage) ( 28 , 31 ) , N1 ( 3 ) , NB-4 (myeloid) ( 249 ) , NCI-H1299 (pulmonary) ( 118 ) , NCI-H157 (pulmonary) ( 118 , 268 ) , NCI-H1650 (pulmonary) ( 82 ) , NCI-H1703 (squamous) ( 83 , 165 ) , NCI-H1781 (pulmonary) ( 84 ) , NCI-H1975 (pulmonary) ( 16 , 19 , 39 , 82 ) , NCI-H1993 (pulmonary) ( 135 ) , NCI-H2073 (pulmonary) ( 83 , 135 ) , NCI-H2106 (pulmonary) ( 82 ) , NCI-H2228 (pulmonary) ( 84 ) , NCI-H2342 (pulmonary) ( 83 ) , NCI-H292 (pulmonary) ( 138 ) , NCI-H3122 (pulmonary) ( 84 ) , NCI-H3255 (pulmonary) ( 97 ) , NCI-H345 (pulmonary) ( 284 ) , NCI-H358 (pulmonary) ( 135 ) , NCI-H441 (pulmonary) ( 135 ) , NCI-H460 (pulmonary) ( 16 , 19 , 221 ) , NCI-H510 (pulmonary) ( 284 ) , NCI-H661 (pulmonary) ( 84 ) , NCI-H69 (pulmonary) ( 284 ) , NCI-H727 (epithelial) ( 22 ) , neuron-'brain, hippocampus' ( 161 ) , neutrophil ( 224 , 308 , 342 , 343 , 351 ) , NL-17 (intestinal) ( 333 ) , NSCLC (pulmonary) ( 347 ) , OAW28 (ovarian) ( 23 ) , OCI-ly7 (B lymphocyte) ( 54 ) , OCI/AML3 (myeloid) ( 31 ) , OK (renal) ( 220 ) , oocyte ( 114 ) , ovary ( 153 ) , OVCAR3 (ovarian) ( 23 , 162 ) , OVCAR5 (ovarian) ( 162 ) , PAE (endothelial) ( 46 , 345 ) , PANC-1 (pancreatic) ( 43 , 192 ) , pancreas ( 43 , 275 ) , PC-12 (chromaffin) ( 252 ) , PC3 (prostate cell) ( 9 , 51 , 78 , 98 , 105 , 120 , 134 , 140 , 143 , 176 , 191 , 206 , 221 , 253 , 274 , 333 , 361 ) , platelet-blood ( 231 , 301 , 332 , 356 ) , pp126 (keratinocyte) ( 323 ) , QGP-1 (endocrine) ( 22 ) , RAMOS (B lymphocyte) ( 287 ) , Rh1 (bone cell) ( 210 ) , Rh13 (muscle cell) ( 307 ) , Rh18 (muscle cell) ( 210 , 307 ) , Rh30 ('muscle, skeletal') ( 210 , 219 , 307 ) , Rh4 (muscle cell) ( 307 ) , Rh41 ( 210 ) , Rh5 (muscle cell) ( 307 ) , RPMI-8266 (plasma cell) ( 10 ) , RWP1 (pancreatic) ( 95 ) , Saos-2 (bone cell) ( 256 ) , SB2 (melanocyte) ( 177 ) , SCC12 (keratinocyte) ( 339 ) , Schwann ( 195 ) , SG231 (hepatic) ( 300 ) , SH-SY5Y (neural crest) ( 123 , 133 , 234 , 240 , 305 , 306 ) , SHEP (neuron) ( 234 , 291 ) , SK-HEP-1 (endothelial) ( 50 ) , SK-LU-1 (pulmonary) ( 135 ) , SK-MEL2 (melanocyte) ( 177 ) , SK-MEL28 (melanocyte) ( 44 ) , SK-MEL5 (melanocyte) ( 177 ) , SK-N-BE(2) (neural crest) ( 234 ) , SK-N-MC (neural crest) ( 291 ) , SKBr3 (breast cell) ( 89 , 138 , 281 ) , SKBR7 (breast cell) ( 35 ) , skin ( 27 , 177 ) , SKNSH (neural crest) ( 234 ) , SKOV-3 (ovarian) ( 36 , 140 , 156 , 162 , 322 ) , SKRC-44 (renal) ( 255 ) , SKUT-1 ( 145 ) , SMMC7721 (hepatocyte) ( 50 ) , SRB-1 (squamous) ( 312 ) , SU-DHL-2 (B lymphocyte) ( 54 ) , Su.86.86 (pancreatic) ( 12 , 43 ) , SUM149 (breast cell) ( 37 ) , SW1463 (intestinal) ( 134 ) , SW48 (intestinal) ( 72 ) , SW620 (intestinal) ( 72 ) , T lymphocyte-blood ( 229 ) , T47D (breast cell) ( 14 , 21 , 71 , 89 , 134 , 303 ) , T84 (intestinal) ( 160 ) , T98G (glial) ( 71 , 129 ) , TF-1 (erythroid) ( 249 , 360 ) , THP1 (myeloid) ( 25 , 352 ) , U-251 MG (glial) ( 239 , 251 ) , U-937 (myeloid) ( 25 , 78 , 175 , 249 , 313 ) , U2OS (bone cell) [GR (human)] ( 321 ) , U2OS (bone cell) ( 81 , 101 , 135 , 159 , 173 , 187 , 190 , 233 , 277 ) , U373 MG (glial) ( 184 ) , U87MG (glial) ( 143 , 173 , 234 , 251 , 266 , 357 ) , UACC-257 (melanocyte) ( 177 ) , UCSD-354L (melanocyte) ( 177 ) , UT-7 (myeloid) [EPO (human), transfection] ( 359 ) , VSMC-aorta ( 149 ) , WI-38 (fibroblast) ( 190 ) , WiDr (epithelial) ( 32 ) , WM-1552 (melanocyte) ( 177 ) , WM1799 (melanocyte) ( 177 ) , WM2664 (melanocyte) ( 177 ) , WM3211 (melanocyte) ( 177 ) , WM35 (melanocyte) ( 177 , 205 ) , WM46 (melanocyte) ( 177 ) , WM793 ( 140 ) , ZR-75-1 (breast cell) ( 89 )

Upstream Regulation
Regulatory protein:	Ack (human) ( 47 ) , ADRA1B (human) ( 320 ) , Akt1 (human) ( 106 , 114 , 140 , 181 , 197 , 211 , 329 , 357 ) , Akt2 (human) ( 181 , 197 ) , AMIGO2 (human) ( 48 ) , APPL (mouse) ( 96 ) , BAP28 (human) ( 43 ) , Bcr (human) ( 6 ) , beclin 1 (human) ( 49 ) , BRAF (human) ( 177 ) , Brk (human) ( 105 , 150 ) , CA9 (human) ( 255 ) , CAMKK1 (human) ( 329 ) , CD133 (human) ( 55 ) , CDK1 (human) ( 17 ) , CHKA (human) ( 194 ) , CHKB (human) ( 194 ) , CIP2A (human) ( 73 ) , CSF2RB (human) ( 302 ) , CYP3A5 (human) ( 57 ) , DDIT4 (human) ( 270 ) , DDIT4L (human) ( 270 ) , DYRK2 (human) ( 21 ) , Epac1 (human) ( 98 ) , ERK1 (human) ( 230 ) , ERK2 (human) ( 230 ) , Etk (human) ( 92 ) , FKBP5 (human) ( 4 ) , FRK (human) ( 187 ) , GAB2 (human) ( 200 ) , GRB2 (human) ( 149 ) , GRP78 (human) ( 141 ) , GSK3A (human) ( 113 ) , HER2 (human) ( 89 ) , HER3 (human) ( 162 ) , HRas (human) ( 140 , 278 , 320 , 362 ) , HSP90A (human) ( 213 ) , IEX-1 (human) ( 230 ) , IKKB (human) ( 203 ) , IKKE (human) ( 118 ) , IL24 (human) ( 52 ) , IL2RA (human) ( 229 ) , ILK (human) ( 206 , 251 , 304 , 310 , 361 ) , INPP4B (human) ( 32 ) , INPP5E (human) ( 334 ) , IRS2 (human) ( 93 ) , KLK1 (human) ( 225 ) , KRas (human) ( 135 , 278 ) , LIMS1 (human) ( 304 ) , LKB1 (human) ( 228 ) , LYN (human) ( 209 ) , MEK1 (human) ( 327 ) , Met (human) ( 70 ) , MINK (human) ( 35 ) , MST2 (human) ( 156 ) , mTOR (human) ( 114 , 181 , 208 ) , MYO6 (human) ( 11 ) , NRas (human) ( 177 ) , OSBPL9 (human) ( 232 ) , P130Cas (human) ( 88 ) , p300 (human) ( 144 ) , p53 (human) ( 190 ) , PAK1 (human) ( 241 ) , PAK1 (rat) ( 197 ) , PAK2 (human) ( 197 , 241 ) , PCAF (human) ( 144 ) , PCTP (human) ( 93 ) , PDK1 (human) ( 118 , 135 , 171 , 213 , 326 ) , PDK1 (mouse) ( 283 , 353 ) , PHLDA3 (human) ( 190 ) , PHLPP (human) ( 110 , 140 , 227 ) , PHLPP2 (human) ( 110 , 140 , 227 ) , PIK3CA (human) ( 140 , 202 , 238 ) , PIK3CG (human) ( 289 ) , PIK3R1 (human) ( 9 , 118 ) , PIK3R2 (human) ( 70 ) , PINK1 (human) ( 133 ) , PKACA (mouse) ( 96 ) , PKCB (human) ( 238 ) , PKCT (mouse) ( 91 ) , PKN1 (human) ( 353 ) , PKN2 (human) ( 353 , 355 ) , PPP1CA (human) ( 148 ) , PPP1R2 (human) ( 240 ) , PPP2CA (human) ( 110 , 166 , 212 ) , PPP2R2A (human) ( 25 , 38 , 40 ) , PPP2R5B (human) ( 230 ) , PRICKLE1 (human) ( 35 ) , PTEN (human) ( 62 , 134 , 233 , 357 , 361 , 362 ) , PTPRJ (human) ( 193 ) , PTPRK (human) ( 55 ) , PXN iso2 (human) ( 169 ) , RAC1 (human) ( 197 ) , Raptor (human) ( 73 , 181 ) , RHEBL1 (human) ( 15 ) , RICTOR (human) ( 135 , 181 , 191 ) , RRas (human) ( 140 ) , SHIP (human) ( 286 ) , SHIP-2 (human) ( 140 ) , SHIP-2 (mouse) ( 357 ) , SHP-1 (human) ( 117 ) , SHPS1 (human) ( 149 ) , Sin1 (human) ( 135 ) , SIRT1 (human) ( 74 , 144 ) , SIRT2 (human) ( 74 ) , SPRY2 (human) ( 259 ) , Src (human) ( 211 , 320 ) , ST3GAL5 (human) ( 61 ) , ST8SIA1 (human) ( 61 ) , TACC3 (human) ( 50 ) , THEM2 (human) ( 93 ) , TIMP1 (human) ( 63 ) , TRAF6 (human) ( 180 ) , ULK1 (human) ( 226 ) , USP49 (human) ( 12 ) , ZFP57 (human) ( 60 )
Putative in vivo kinases:	AXL (human) ( 26 ) , IKKE (human) ( 118 ) , Mer (human) ( 26 ) , PDK1 (human) ( 51 , 134 , 149 , 328 , 333 ) , PIK3CA (human) ( 93 ) , PRKD1 (human) ( 326 ) , TBK1 (human) ( 135 ) , Tyro3 (human) ( 26 )
Kinases, in vitro:	IKKE (human) ( 118 ) , PDK1 (human) ( 254 , 274 , 333 , 363 , 368 ) , PKCA (human) ( 356 ) , PKCB (human) ( 356 ) , TBK1 (human) ( 135 )
Putative upstream phosphatases:	PPP2CA (human) ( 43 , 186 ) , PTEN (human) ( 23 )
Phosphatases, in vitro:	PPP2CA (human) ( 212 ) , PTEN (human) ( 23 )
Treatments:	1-methyladenine ( 114 ) , 2-deoxyglucose ( 298 ) , 4-DAMP ( 99 ) , 4-HT ( 174 , 211 , 326 ) , 5-cholesten-5-beta-ol ( 158 ) , 8-CPT-2Me-cAMP ( 98 ) , 8-Rp-cAMP ( 246 ) , 9cRA ( 174 ) , A-443654 ( 154 ) , actinomycin_D ( 155 ) , activin ( 103 ) , ADA ( 224 ) , adiponectin ( 186 , 228 ) , adriamycin ( 180 ) , afatinib ( 39 ) , AG1024 ( 303 ) , AG1296 ( 303 ) , AG1478 ( 133 , 158 , 280 , 303 ) , AGK2 ( 74 ) , Akt-I-1 ( 166 , 220 , 282 ) , Akt-I-1,2 ( 282 ) , Akt_inhibitor_VIII ( 133 , 151 ) , alpelisib ( 22 ) , alpha-mangostin ( 142 ) , amino_acids ( 260 , 321 ) , angiotensin ( 294 ) , anti-Akt1 ( 269 ) , anti-CD3/CD28 ( 229 ) , anti-E-cadherin ( 323 ) , anti-HER2 ( 281 ) , anti-HLA ( 208 ) , anti-ICAM-2 ( 337 ) , anti-IgM ( 20 , 238 ) , anti-integrin_alpha9beta1 ( 140 ) , anti-PDGFR ( 303 ) , apelin ( 285 ) , API-2 ( 118 ) , arachidonic_acid ( 343 ) , atiprimod ( 237 ) , AZD8055 ( 173 ) , BAPTA-AM ( 253 , 301 , 356 ) , BAR501 ( 64 ) , BCI-121 ( 24 ) , BDNF ( 59 ) , bisindolylmaleimide ( 238 , 356 ) , BQ-123 ( 280 ) , BQ-788 ( 280 ) , bradykinin ( 345 ) , bumetanide ( 235 ) , C2-ceramide ( 353 ) , C6-ceramide ( 36 , 360 ) , caffeine ( 295 ) , calyculin_A ( 140 , 231 , 235 , 246 , 253 , 360 ) , cAMP_analog ( 195 ) , cangrelor ( 301 ) , carbachol ( 99 ) , CAY10399 ( 224 ) , CCCP ( 305 ) , celastrol ( 78 ) , celecoxib ( 300 , 328 ) , cell_adhesion ( 175 ) , CGS_21680 ( 224 ) , cholesterol ( 158 ) , cholesterol_oxidase ( 158 ) , ciclosporin ( 129 , 253 ) , cisplatin ( 180 ) , colforsin ( 195 , 224 , 246 , 349 ) , collagen ( 332 ) , collagen XIX (NC1 domain) ( 44 ) , compound_7 ( 134 ) , conditioned medium ( 31 ) , convulxin ( 332 ) , CTGF ( 279 ) , culturing_of_cells ( 161 , 238 ) , CXCL12 ( 238 , 241 ) , cyclic_stretch ( 280 ) , cycloheximide ( 116 ) , dactolisib ( 104 , 202 ) , dasatinib ( 140 ) , decorin ( 340 ) , deoxygenation ( 76 ) , depolarization ( 240 ) , derivative-2 ( 67 ) , dexamethasone ( 174 ) , DMSO ( 202 , 211 ) , dronabinol ( 244 ) , duvelisib ( 31 ) , EF24 ( 218 ) , EGF ( 5 , 11 , 36 , 74 , 110 , 113 , 133 , 135 , 150 , 156 , 200 , 227 , 242 , 245 , 255 , 283 , 295 , 303 , 311 , 349 ) , EGTA ( 99 ) , englerin_A ( 91 ) , ephrin_A1 ( 140 , 184 ) , Epo ( 230 , 359 ) , erbstatin ( 338 ) , erlotinib ( 56 ) , estrogen_deprivation ( 267 ) , ethanol ( 140 , 323 ) , exercise training ( 139 ) , fasting ( 75 ) , FGF2 ( 103 , 259 ) , fibronectin ( 86 ) , Filipin ( 158 ) , fingolimod ( 25 , 28 , 313 ) , FL ( 28 ) , fluid_shear_stress ( 335 ) , FMK-MEA ( 72 ) , fMLP ( 224 , 342 , 343 ) , FTI277 ( 278 ) , ganglioside ( 339 ) , gefitinib ( 56 , 97 ) , genistein ( 338 ) , GF109203X ( 285 , 301 ) , GH ( 75 ) , ghrelin ( 117 ) , glabridin ( 109 ) , glucose ( 135 , 201 ) , glucose_starvation ( 223 ) , GM-CSF ( 360 ) , Go_6976 ( 356 ) , growth_factor_withdrawal ( 152 ) , GSK2334470 ( 10 , 14 , 51 ) , GSK690693 ( 118 ) , H-89 ( 224 , 320 ) , H2O2 ( 151 , 152 , 171 , 199 , 235 ) , heat_shock ( 296 , 305 ) , hepatitis C virus expression ( 7 ) , heregulin ( 103 ) , HGF ( 33 , 57 , 70 , 86 , 299 ) , high-fat diet ( 117 , 371 ) , HNMPA(AM)3 ( 179 ) , HU-210 ( 317 ) , hypotonic_buffer ( 235 ) , hypoxia ( 185 ) , hypoxia/reoxygenation ( 254 ) , ibrutinib ( 8 , 54 ) , IC87114 ( 224 ) , ICAM-2 ( 337 ) , idelalisib ( 20 ) , IFN-gamma ( 160 ) , IGF-1 ( 49 , 103 , 147 , 149 , 167 , 180 , 210 , 216 , 235 , 258 , 272 , 303 , 304 , 305 , 322 , 347 , 370 ) , IGF-2 ( 60 , 307 ) , IgG ( 323 ) , IL-13 ( 328 ) , IL-1a ( 94 ) , IL-1b ( 180 , 329 ) , IL-3 ( 212 ) , IL-6 ( 261 ) , imatinib ( 140 ) , insulin ( 30 , 74 , 79 , 93 , 96 , 110 , 116 , 118 , 122 , 135 , 136 , 139 , 151 , 154 , 166 , 181 , 189 , 207 , 221 , 223 , 226 , 228 , 259 , 260 , 261 , 262 , 268 , 271 , 276 , 283 , 294 , 298 , 305 , 314 , 315 , 319 , 321 , 324 , 330 , 338 , 341 , 344 , 353 , 370 , 371 ) , ionomycin ( 99 , 329 ) , IP(6) ( 176 ) , IQA ( 264 ) , isoproterenol ( 320 ) , isosilybin_B ( 204 ) , K252a ( 279 ) , KCl ( 235 ) , KHS101 ( 50 ) , KN-93 ( 99 ) , KP-372-1 ( 249 ) , KP-392 ( 361 ) , KU-0063794 ( 78 ) , LAM ( 352 ) , laminin-1 ( 86 ) , leptin ( 338 ) , linoleic_acid ( 79 ) , losartan ( 280 , 294 ) , low_glucose ( 144 ) , LPA ( 303 , 327 ) , LPS ( 45 , 135 , 180 , 350 ) , LY294002 ( 70 , 74 , 101 , 103 , 116 , 118 , 135 , 140 , 158 , 166 , 167 , 194 , 201 , 216 , 221 , 230 , 236 , 238 , 242 , 244 , 245 , 246 , 257 , 264 , 268 , 280 , 297 , 299 , 301 , 309 , 316 , 317 , 320 , 323 , 326 , 327 , 332 , 338 , 346 , 347 , 350 , 353 , 354 , 356 , 357 , 360 ) , LY333531 ( 238 ) , major_basic_protein ( 308 ) , mastoparan ( 317 ) , methyl-beta-cyclodextrin ( 158 ) , MG132 ( 243 ) , MK-2206 ( 25 , 59 , 101 , 118 ) , Mn(2+) ( 140 ) , N6-benzoyl-cAMP ( 98 ) , NAC ( 152 ) , naltrindole ( 284 ) , neuregulin ( 162 , 195 ) , neurotrophin-3 ( 59 ) , NGF ( 252 , 306 ) , nicotinamide ( 74 , 144 ) , nicotine ( 293 ) , NS398 ( 273 ) , okadaic_acid ( 43 , 114 , 116 , 119 , 140 , 152 , 166 , 175 , 186 , 243 , 253 , 268 , 313 , 360 ) , oleic_acid ( 79 ) , OSI-027 ( 104 ) , OSU-03012 ( 41 , 219 ) , OSU-T315 ( 372 ) , ouabain ( 220 ) , PAR1-activating_peptide ( 301 ) , PAR4-activating_peptide ( 301 ) , PD0325901 ( 72 ) , PD168393 ( 280 ) , PD98059 ( 140 , 257 , 316 , 327 , 342 ) , PDGF ( 169 , 197 , 216 , 295 , 296 , 303 , 334 , 367 ) , PDK1_inhibitor_3 ( 143 ) , pemetrexed ( 16 , 19 , 37 ) , perifosine ( 118 ) , PGE2 ( 224 ) , phorbol_ester ( 65 , 235 , 236 , 238 , 301 , 315 , 321 , 344 , 356 ) , PI-103 ( 133 , 202 ) , pictilisib ( 93 ) , PIK-93 ( 202 ) , PIK90 ( 202 ) , pimenta doica ( 53 ) , PKC_inhibitor_myristoylated ( 285 ) , PKI-402 ( 159 ) , PLS-123 ( 54 ) , PLTP ( 179 ) , PP-110 ( 202 ) , PP1 ( 257 ) , PP2 ( 140 , 193 , 320 ) , PP242 ( 10 , 72 , 147 , 155 , 189 ) , PP30 ( 189 ) , PTP1B_inhibitor ( 122 ) , PTX ( 280 , 285 , 327 ) , PUGNAc ( 106 ) , QLT0254 ( 275 ) , racepinefrine ( 99 , 136 ) , rapamycin ( 29 , 72 , 93 , 110 , 140 , 147 , 155 , 173 , 205 , 210 , 228 , 257 , 285 , 298 , 321 , 354 ) , resveratrol ( 144 , 151 ) , retinoic_acid ( 155 , 174 ) , rimonabant ( 317 ) , Ro31-8220 ( 236 ) , salicylate ( 315 , 354 ) , sardomozide ( 196 ) , SB203580 ( 327 , 351 ) , SCF ( 236 ) , scratch wound ( 76 ) , selenite ( 253 ) , serum ( 3 , 101 , 180 , 184 , 197 , 202 , 212 , 221 , 239 , 245 , 256 , 295 , 347 , 361 ) , serum_starvation ( 132 , 230 ) , serum_withdrawal ( 250 ) , SH-5 ( 238 ) , SH-6 ( 239 , 285 ) , sildenafil ( 16 , 19 ) , silmitasertib ( 120 , 146 ) , simvastatin ( 158 ) , SiO2 @AM/CN ( 18 ) , siRNA ( 118 , 135 , 193 , 197 , 203 , 206 , 209 , 218 , 227 , 232 , 241 , 304 ) , sonolisib ( 58 ) , sorafenib ( 16 , 37 ) , sorbitol ( 235 ) , SP600125 ( 78 , 254 , 315 ) , sphingosine_1-phosphate ( 303 , 327 ) , sphingosylphosphorylcholine ( 15 ) , starvation_medium ( 103 ) , staurosporine ( 78 , 272 , 333 , 344 ) , STO-609 ( 99 ) , Su11274 ( 70 ) , SU6656 ( 211 ) , tamoxifen ( 174 , 211 ) , tautomycetin ( 166 ) , tautomycin ( 140 ) , TBB ( 264 ) , temsirolimus ( 145 ) , TGF-alpha ( 5 ) , TGF-beta ( 9 ) , thapsigargin ( 96 ) , thrombin ( 301 , 332 , 356 ) , TNF ( 160 , 203 , 207 , 235 , 280 , 315 ) , Torin1 ( 65 , 111 , 112 ) , TPO ( 230 , 356 ) , tunicamycin ( 141 ) , U0126 ( 65 , 220 , 244 , 298 ) , UCN-01 ( 154 , 291 , 333 ) , UV ( 346 ) , V-100 ( 254 ) , valproic_acid ( 23 ) , vanadate ( 213 , 235 , 322 , 341 ) , VEGF ( 48 ) , virus infection ( 135 , 207 , 256 , 324 ) , wortmannin ( 78 , 93 , 118 , 133 , 158 , 199 , 224 , 257 , 280 , 285 , 296 , 298 , 307 , 311 , 316 , 317 , 321 , 327 , 332 , 335 , 338 , 342 , 347 , 349 , 350 , 353 , 355 , 370 )

Downstream Regulation
Effects of modification on Akt1:	activity, induced ( 281 , 288 , 305 , 323 , 347 , 352 , 369 ) , enzymatic activity, induced ( 51 , 74 , 93 , 118 , 132 , 178 , 197 , 201 , 256 , 296 , 301 , 309 , 311 , 316 , 346 , 362 , 367 , 368 , 370 ) , intracellular localization ( 153 , 159 , 197 , 216 , 305 , 357 ) , molecular association, regulation ( 9 , 197 , 256 , 369 ) , phosphorylation ( 114 , 135 , 144 , 353 ) , protein conformation ( 216 )
Effects of modification on biological processes:	apoptosis, altered ( 149 ) , apoptosis, inhibited ( 135 , 146 , 347 , 355 ) , carcinogenesis, induced ( 118 , 135 , 146 , 177 ) , cell cycle regulation ( 146 , 281 ) , cell growth, altered ( 160 , 212 ) , cell growth, induced ( 32 , 59 , 146 ) , cell growth, inhibited ( 159 ) , cell motility, altered ( 197 , 331 ) , cell motility, induced ( 70 , 146 ) , cytoskeletal reorganization ( 348 ) , signaling pathway regulation ( 70 , 79 , 135 , 146 ) , transcription, altered ( 346 ) , transcription, induced ( 80 )
Induce interaction with:	PAK1 (human) ( 197 ) , PDK1 (human) ( 197 ) , PPP2CA (human) ( 256 ) , TGFBR3 (human) ( 9 ) , TRAF6 (human) ( 9 )

Disease / Diagnostics Relevance
Relevant diseases:	HNSCC ( 137 ) , chronic lymphocytic leukemia ( 238 ) , neuroblastoma ( 234 ) , ovarian cancer ( 153 ) , pancreatic cancer ( 43 ) , Kaposi's sarcoma ( 121 ) , melanoma skin cancer ( 177 ) , rhabdomyosarcoma ( 219 ) , diabetes mellitus ( 225 ) , type 2 diabetes ( 139 , 265 )

References
1	Miller WP, et al. (2020) The stress response protein REDD1 promotes diabetes-induced oxidative stress in the retina by Keap1-independent Nrf2 degradation. J Biol Chem 32295843 Curated Info
2	Han F, et al. (2018) The critical role of AMPK in driving Akt activation under stress, tumorigenesis and drug resistance. Nat Commun 9, 4728 30413706 Curated Info
3	Ohmi Y, et al. (2018) Differential roles of gangliosides in malignant properties of melanomas. PLoS One 13, e0206881 30462668 Curated Info
4	Dong J, et al. (2017) FKBP51 decreases cell proliferation and increases progestin sensitivity of human endometrial adenocarcinomas by inhibiting Akt. Oncotarget 8, 80405-80415 29113312 Curated Info
5	Guo J, et al. (2017) PRAS40 Connects Microenvironmental Stress Signaling to Exosome-Mediated Secretion. Mol Cell Biol 37 28674187 Curated Info
6	Havranek O, et al. (2017) Tonic B-cell receptor signaling in diffuse large B-cell lymphoma. Blood 130, 995-1006 28646116 Curated Info
7	Lerat H, et al. (2017) Hepatitis C virus induces a prediabetic state by directly impairing hepatic glucose metabolism in mice. J Biol Chem 292, 12860-12873 28559285 Curated Info
8	Patel V, et al. (2017) Comparison of Acalabrutinib, A Selective Bruton Tyrosine Kinase Inhibitor, with Ibrutinib in Chronic Lymphocytic Leukemia Cells. Clin Cancer Res 23, 3734-3743 28034907 Curated Info
9	Hamidi A, et al. (2017) TGF-β promotes PI3K-AKT signaling and prostate cancer cell migration through the TRAF6-mediated ubiquitylation of p85α. Sci Signal 10 28676490 Curated Info
10	Yang C, et al. (2017) PDK1 inhibitor GSK2334470 exerts antitumor activity in multiple myeloma and forms a novel multitargeted combination with dual mTORC1/C2 inhibitor PP242. Oncotarget 8, 39185-39197 28402933 Curated Info
11	Masters TA, Tumbarello DA, Chibalina MV, Buss F (2017) MYO6 Regulates Spatial Organization of Signaling Endosomes Driving AKT Activation and Actin Dynamics. Cell Rep 19, 2088-2101 28591580 Curated Info
12	Luo K, et al. (2017) USP49 negatively regulates tumorigenesis and chemoresistance through FKBP51-AKT signaling. EMBO J 36, 1434-1446 28363942 Curated Info
13	Chen YX, et al. (2017) Novel Akt activator SC-79 is a potential treatment for alcohol-induced osteonecrosis of the femoral head. Oncotarget 8, 31065-31078 28415692 Curated Info
14	Jansen VM, et al. (2017) Kinome-Wide RNA Interference Screen Reveals a Role for PDK1 in Acquired Resistance to CDK4/6 Inhibition in ER-Positive Breast Cancer. Cancer Res 77, 2488-2499 28249908 Curated Info
15	Kim HJ, et al. (2017) Novel involvement of RhebL1 in sphingosylphosphorylcholine-induced keratin phosphorylation and reorganization: Binding to and activation of AKT1. Oncotarget 8, 20851-20864 28209923 Curated Info
16	Booth L, Roberts JL, Poklepovic A, Dent P (2017) PDE5 inhibitors enhance the lethality of [pemetrexed + sorafenib]. Oncotarget 8, 13464-13475 28088782 Curated Info
17	Wang XQ, et al. (2017) CDK1-PDK1-PI3K/Akt signaling pathway regulates embryonic and induced pluripotency. Cell Death Differ 24, 38-48 27636107 Curated Info
18	Dehghany Ashkezary M, Aboee-Mehrizi F, Moradi P (2017) SiO2@antisense molecules covered by nepetalactone, extracted from Nepeta gloeocephala, inhibits ILK phosphorylation and downstream PKB/AKT signaling in HeLa cells. Cancer Gene Ther 24, 28-32 27982018 Curated Info
19	Booth L, et al. (2017) PDE5 inhibitors enhance the lethality of pemetrexed through inhibition of multiple chaperone proteins and via the actions of cyclic GMP and nitric oxide. Oncotarget 8, 1449-1468 27903966 Curated Info
20	Yang Q, et al. (2017) Idelalisib Impacts Cell Growth through Inhibiting Translation-Regulatory Mechanisms in Mantle Cell Lymphoma. Clin Cancer Res 23, 181-192 27342398 Curated Info
21	Mimoto R, et al. (2017) Diminished DYRK2 sensitizes hormone receptor-positive breast cancer to everolimus by the escape from degrading mTOR. Cancer Lett 384, 27-38 27746162 Curated Info
22	Nölting S, et al. (2017) The selective PI3Kα inhibitor BYL719 as a novel therapeutic option for neuroendocrine tumors: Results from multiple cell line models. PLoS One 12, e0182852 28800359 Curated Info
23	Phadngam S, et al. (2016) PTEN dephosphorylates AKT to prevent the expression of GLUT1 on plasmamembrane and to limit glucose consumption in cancer cells. Oncotarget 7, 84999-85020 27829222 Curated Info
24	Yoshioka Y, et al. (2016) SMYD3-mediated lysine methylation in the PH domain is critical for activation of AKT1. Oncotarget 7, 75023-75037 27626683 Curated Info
25	Shouse G, et al. (2016) Novel B55α-PP2A mutations in AML promote AKT T308 phosphorylation and sensitivity to AKT inhibitor-induced growth arrest. Oncotarget 7, 61081-61092 27531894 Curated Info
26	Kimani SG, et al. (2016) Normalization of TAM post-receptor signaling reveals a cell invasive signature for Axl tyrosine kinase. Cell Commun Signal 14, 19 27595981 Curated Info
27	Choi YJ, et al. (2016) The underlying mechanism of proinflammatory NF-κB activation by the mTORC2/Akt/IKKα pathway during skin aging. Oncotarget 7, 52685-52694 27486771 Curated Info
28	Smith AM, et al. (2016) Activation of protein phosphatase 2A in FLT3+ acute myeloid leukemia cells enhances the cytotoxicity of FLT3 tyrosine kinase inhibitors. Oncotarget 7, 47465-47478 27329844 Curated Info
29	Watari K, et al. (2016) Phosphorylation of mTOR Ser2481 is a key target limiting the efficacy of rapalogs for treating hepatocellular carcinoma. Oncotarget 7, 47403-47417 27329724 Curated Info
30	Rajan MR, et al. (2016) Systems-wide Experimental and Modeling Analysis of Insulin Signaling through Forkhead Box Protein O1 (FOXO1) in Human Adipocytes, Normally and in Type 2 Diabetes. J Biol Chem 291, 15806-15819 27226562 Curated Info
31	Pillinger G, et al. (2016) Targeting PI3Kδ and PI3Kγ signalling disrupts human AML survival and bone marrow stromal cell mediated protection. Oncotarget 7, 39784-39795 27174919 Curated Info
32	Guo ST, et al. (2016) INPP4B is an oncogenic regulator in human colon cancer. Oncogene 35, 3049-61 26411369 Curated Info
33	Wu Y, et al. (2016) PKG II reverses HGF-triggered cellular activities by phosphorylating serine 985 of c-Met in gastric cancer cells. Oncotarget 7, 34190-200 27147579 Curated Info
34	Mertins P, et al. (2016) Proteogenomics connects somatic mutations to signalling in breast cancer. Nature 534, 55-62 27251275 Curated Info
35	Daulat AM, et al. (2016) PRICKLE1 Contributes to Cancer Cell Dissemination through Its Interaction with mTORC2. Dev Cell 37, 311-25 27184734 Curated Info
36	Kitatani K, et al. (2016) Ceramide limits phosphatidylinositol-3-kinase C2β-controlled cell motility in ovarian cancer: potential of ceramide as a metastasis-suppressor lipid. Oncogene 35, 2801-12 26364609 Curated Info
37	Booth L, et al. (2016) [Pemetrexed + Sorafenib] lethality is increased by inhibition of ERBB1/2/3-PI3K-NFκB compensatory survival signaling. Oncotarget 7, 23608-32 27015562 Curated Info
38	Hein AL, et al. (2016) PR55α Subunit of Protein Phosphatase 2A Supports the Tumorigenic and Metastatic Potential of Pancreatic Cancer Cells by Sustaining Hyperactive Oncogenic Signaling. Cancer Res 76, 2243-53 26893480 Curated Info
39	Booth L, et al. (2016) The afatinib resistance of in vivo generated H1975 lung cancer cell clones is mediated by SRC/ERBB3/c-KIT/c-MET compensatory survival signaling. Oncotarget 7, 19620-30 26934000 Curated Info
40	Bousquet E, et al. (2016) RhoB loss induces Rac1-dependent mesenchymal cell invasion in lung cells through PP2A inhibition. Oncogene 35, 1760-9 26148238 Curated Info
41	Booth L, et al. (2016) Multi-kinase inhibitors can associate with heat shock proteins through their NH2-termini by which they suppress chaperone function. Oncotarget 7, 12975-96 26887051 Curated Info
42	Lin CH, Liu SY, Lee EH (2016) SUMO modification of Akt regulates global SUMOylation and substrate SUMOylation specificity through Akt phosphorylation of Ubc9 and SUMO1. Oncogene 35, 595-607 25867063 Curated Info
43	Liu T, et al. (2016) HEATR1 Negatively Regulates Akt to Help Sensitize Pancreatic Cancer Cells to Chemotherapy. Cancer Res 76, 572-81 26676747 Curated Info
44	Oudart JB, et al. (2016) The anti-tumor NC1 domain of collagen XIX inhibits the FAK/ PI3K/Akt/mTOR signaling pathway through αvβ3 integrin interaction. Oncotarget 7, 1516-28 26621838 Curated Info
45	Rittig N, et al. (2016) Regulation of Lipolysis and Adipose Tissue Signaling during Acute Endotoxin-Induced Inflammation: A Human Randomized Crossover Trial. PLoS One 11, e0162167 27627109 Curated Info
46	Frías A, et al. (2015) A Switch in Akt Isoforms Is Required for Notch-Induced Snail1 Expression and Protection from Cell Death. Mol Cell Biol 36, 923-40 26711268 Curated Info
47	Lei X, et al. (2015) Ack1 overexpression promotes metastasis and indicates poor prognosis of hepatocellular carcinoma. Oncotarget 6, 40622-41 26536663 Curated Info
48	Park H, et al. (2015) AMIGO2, a novel membrane anchor of PDK1, controls cell survival and angiogenesis via Akt activation. J Cell Biol 211, 619-37 26553931 Curated Info
49	Rohatgi RA, et al. (2015) Beclin 1 regulates growth factor receptor signaling in breast cancer. Oncogene 34, 5352-62 25639875 Curated Info
50	Zhou DS, et al. (2015) TACC3 promotes stemness and is a potential therapeutic target in hepatocellular carcinoma. Oncotarget 6, 24163-77 26219398 Curated Info
51	Yang G, Murashige DS, Humphrey SJ, James DE (2015) A Positive Feedback Loop between Akt and mTORC2 via SIN1 Phosphorylation. Cell Rep 12, 937-43 26235620 Curated Info
52	Panneerselvam J, et al. (2015) Phosphorylation of interleukin (IL)-24 is required for mediating its anti-cancer activity. Oncotarget 6, 16271-86 26009991 Curated Info
53	Zhang L, et al. (2015) Polyphenol-rich extract of Pimenta dioica berries (Allspice) kills breast cancer cells by autophagy and delays growth of triple negative breast cancer in athymic mice. Oncotarget 6, 16379-95 25945840 Curated Info
54	Ding N, et al. (2015) Irreversible dual inhibitory mode: the novel Btk inhibitor PLS-123 demonstrates promising anti-tumor activity in human B-cell lymphoma. Oncotarget 6, 15122-36 25944695 Curated Info
55	Shimozato O, et al. (2015) Receptor-type protein tyrosine phosphatase κ directly dephosphorylates CD133 and regulates downstream AKT activation. Oncogene 34, 1949-60 24882578 Curated Info
56	Kim Y, et al. (2015) Differential Effects of Tyrosine Kinase Inhibitors on Normal and Oncogenic EGFR Signaling and Downstream Effectors. Mol Cancer Res 13, 765-74 25573954 Curated Info
57	Jiang F, et al. (2015) CYP3A5 Functions as a Tumor Suppressor in Hepatocellular Carcinoma by Regulating mTORC2/Akt Signaling. Cancer Res 75, 1470-81 25649767 Curated Info
58	Ghosh JC, et al. (2015) Adaptive mitochondrial reprogramming and resistance to PI3K therapy. J Natl Cancer Inst 107 25650317 Curated Info
59	Lawn S, et al. (2015) Neurotrophin signaling via TrkB and TrkC receptors promotes the growth of brain tumor-initiating cells. J Biol Chem 290, 3814-24 25538243 Curated Info
60	Tada Y, et al. (2015) The stem cell transcription factor ZFP57 induces IGF2 expression to promote anchorage-independent growth in cancer cells. Oncogene 34, 752-60 24469060 Curated Info
61	Ma H, et al. (2015) Modification of sialylation is associated with multidrug resistance in human acute myeloid leukemia. Oncogene 34, 726-40 24531716 Curated Info
62	Mense SM, et al. (2015) PTEN inhibits PREX2-catalyzed activation of RAC1 to restrain tumor cell invasion. Sci Signal 8, ra32 25829446 Curated Info
63	Nalluri S, et al. (2015) TIMP-1 Inhibits Apoptosis in Lung Adenocarcinoma Cells via Interaction with Bcl-2. PLoS One 10, e0137673 26366732 Curated Info
64	Renga B, et al. (2015) Reversal of Endothelial Dysfunction by GPBAR1 Agonism in Portal Hypertension Involves a AKT/FOXOA1 Dependent Regulation of H2S Generation and Endothelin-1. PLoS One 10, e0141082 26539823 Curated Info
65	Leontieva OV, Blagosklonny MV (2014) Tumor promoter-induced cellular senescence: cell cycle arrest followed by geroconversion. Oncotarget 5, 12715-27 25587030 Curated Info
66	Humphrey RK, et al. (2014) Loss of TRB3 Alters Dynamics of MLK3-JNK Signaling and Inhibits Cytokine-activated Pancreatic Beta Cell Death. J Biol Chem 289, 29994-30004 25204656 Curated Info
67	Watanabe T, et al. (2014) Pyrrolidinium fullerene induces apoptosis by activation of procaspase-9 via suppression of Akt in primary effusion lymphoma. Biochem Biophys Res Commun 451, 93-100 25063029 Curated Info
68	Niedan S, et al. (2014) Suppression of FOXO1 is responsible for a growth regulatory repressive transcriptional sub-signature of EWS-FLI1 in Ewing sarcoma. Oncogene 33, 3927-38 23995784 Curated Info
69	Saha A, et al. (2014) Akt phosphorylation and regulation of transketolase is a nodal point for amino Acid control of purine synthesis. Mol Cell 55, 264-76 24981175 Curated Info
70	Usatyuk PV, et al. (2014) Role of c-Met/phosphatidylinositol 3-kinase (PI3k)/Akt signaling in hepatocyte growth factor (HGF)-mediated lamellipodia formation, reactive oxygen species (ROS) generation, and motility of lung endothelial cells. J Biol Chem 289, 13476-91 24634221 Curated Info
71	Liu P, et al. (2014) Cell-cycle-regulated activation of Akt kinase by phosphorylation at its carboxyl terminus. Nature 508, 541-5 24670654 Curated Info
72	Ducker GS, et al. (2014) Incomplete inhibition of phosphorylation of 4E-BP1 as a mechanism of primary resistance to ATP-competitive mTOR inhibitors. Oncogene 33, 1590-600 23542178 Curated Info
73	Puustinen P, et al. (2014) CIP2A oncoprotein controls cell growth and autophagy through mTORC1 activation. J Cell Biol 204, 713-27 24590173 Curated Info
74	Ramakrishnan G, et al. (2014) Sirt2 Deacetylase Is a Novel AKT Binding Partner Critical for AKT Activation by Insulin. J Biol Chem 289, 6054-66 24446434 Curated Info
75	Nellemann B, et al. (2014) Growth hormone-induced insulin resistance in human subjects involves reduced pyruvate dehydrogenase activity. Acta Physiol (Oxf) 210, 392-402 24148194 Curated Info
76	Dunn CA, Lampe PD (2014) Injury-triggered Akt phosphorylation of Cx43: a ZO-1-driven molecular switch that regulates gap junction size. J Cell Sci 127, 455-64 24213533 Curated Info
77	Treebak JT, et al. (2014) Acute exercise and physiological insulin induce distinct phosphorylation signatures on TBC1D1 and TBC1D4 proteins in human skeletal muscle. J Physiol 592, 351-75 24247980 Curated Info
78	Peng B, et al. (2014) Peptide deformylase inhibitor actinonin reduces celastrol's HSP70 induction while synergizing proliferation inhibition in tumor cells. BMC Cancer 14, 146 24589236 Curated Info
79	Nardi F, et al. (2014) Enhanced Insulin Sensitivity Associated with Provision of Mono and Polyunsaturated Fatty Acids in Skeletal Muscle Cells Involves Counter Modulation of PP2A. PLoS One 9, e92255 24632852 Curated Info
80	Nguyen le XT, Mitchell BS (2013) Akt activation enhances ribosomal RNA synthesis through casein kinase II and TIF-IA. Proc Natl Acad Sci U S A 110, 20681-6 24297901 Curated Info
81	Piovan E, et al. (2013) Direct Reversal of Glucocorticoid Resistance by AKT Inhibition in Acute Lymphoblastic Leukemia. Cancer Cell 24, 766-76 24291004 Curated Info
82	Rikova K, Hall B (2013) CST Curation Set: 20738, 21165, 30164, 30165, 30166; Year: 2013; Biosample/Treatment: cell line, H1650, HCC827, H1975, Calu-3, H2106; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY, p[ST], RXXp[ST], pSQ, p[ST]QG, LXRXXp[ST], p[ST]P Curated Info
83	Rikova K, Hall B (2013) CST Curation Set: 20739, 21166, 30167, 30168, 30169; Year: 2013; Biosample/Treatment: cell line, H2342, H2073, Lou-NH91, HCC15, H1703; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY, p[ST], RXXp[ST], pSQ, p[ST]QG, LXRXXp[ST], p[ST]P Curated Info
84	Rikova K, Hall B (2013) CST Curation Set: 20740, 21167, 30170, 30171, 30172; Year: 2013; Biosample/Treatment: cell line, H2228, H3122, HCC78, H661, H1781; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY, p[ST], RXXp[ST], pSQ, p[ST]QG, LXRXXp[ST], p[ST]P Curated Info
85	Risso G, et al. (2013) Modification of Akt by SUMO conjugation regulates alternative splicing and cell cycle. Cell Cycle 12, 3165-74 24013425 Curated Info
86	Li Y, Huang X, Zhang Q, Ma K (2013) Phosphorylation of cMet tyrosine residues in murine ascitic hepatic cancer cell lines with different lymph node metastatic potentials. Mol Med Rep 8, 655-61 23778885 Curated Info
87	Humphrey SJ, et al. (2013) Dynamic Adipocyte Phosphoproteome Reveals that Akt Directly Regulates mTORC2. Cell Metab 17, 1009-20 23684622 Curated Info
88	Zhang P, et al. (2013) Identification and functional characterization of p130Cas as a substrate of protein tyrosine phosphatase nonreceptor 14. Oncogene 32, 2087-95 22710723 Curated Info
89	Zhao R, et al. (2013) CDK inhibitor p57 (Kip2) is downregulated by Akt during HER2-mediated tumorigenicity. Cell Cycle 12, 935-43 23421998 Curated Info
90	Munoz C, et al. (2013) Up-regulation of the inwardly rectifying K⁺ channel Kir2.1 (KCNJ2) by protein kinase B (PKB/Akt) and PIKfyve. J Membr Biol 246, 189-97 23188060 Curated Info
91	Sourbier C, et al. (2013) Englerin A stimulates PKCθ to inhibit insulin signaling and to simultaneously activate HSF1: pharmacologically induced synthetic lethality. Cancer Cell 23, 228-37 23352416 Curated Info
92	Chen S, et al. (2013) Tyrosine Kinase BMX Phosphorylates Phosphotyrosine-Primed Motif Mediating the Activation of Multiple Receptor Tyrosine Kinases. Sci Signal 6, ra40 23716717 Curated Info
93	Ersoy BA, et al. (2013) Phosphatidylcholine transfer protein interacts with thioesterase superfamily member 2 to attenuate insulin signaling. Sci Signal 6, ra64 23901139 Curated Info
94	Gulen MF, et al. (2012) Inactivation of the enzyme GSK3α by the kinase IKKi promotes AKT-mTOR signaling pathway that mediates interleukin-1-induced Th17 cell maintenance. Immunity 37, 800-12 23142783 Curated Info
95	Villagrasa P, et al. (2012) Akt2 interacts with Snail1 in the E-cadherin promoter. Oncogene 31, 4022-33 22158034 Curated Info
96	Liu M, et al. (2012) Phosphorylation of Adaptor Protein Containing Pleckstrin Homology Domain, Phosphotyrosine Binding Domain, and Leucine Zipper Motif 1 (APPL1) at Ser430 Mediates Endoplasmic Reticulum (ER) Stress-induced Insulin Resistance in Hepatocytes. J Biol Chem 287, 26087-93 22685300 Curated Info
97	Stokes MP, et al. (2012) PTMScan Direct: Identification and Quantification of Peptides from Critical Signaling Proteins by Immunoaffinity Enrichment Coupled with LC-MS/MS. Mol Cell Proteomics 11, 187-201 22322096 Curated Info
98	Misra UK, Pizzo SV (2012) Upregulation of mTORC2 activation by the selective agonist of EPAC, 8-CPT-2Me-cAMP, in prostate cancer cells: assembly of a multiprotein signaling complex. J Cell Biochem 113, 1488-500 22173835 Curated Info
99	Schmitt JM, Smith S, Hart B, Fletcher L (2012) CaM kinase control of AKT and LNCaP cell survival. J Cell Biochem 113, 1514-26 22173970 Curated Info
100	Beli P, et al. (2012) Proteomic Investigations Reveal a Role for RNA Processing Factor THRAP3 in the DNA Damage Response. Mol Cell 46, 212-25 22424773 Curated Info
101	Li P, et al. (2012) P90 RSK arranges Chk1 in the nucleus for monitoring of genomic integrity during cell proliferation. Mol Biol Cell 23, 1582-92 22357623 Curated Info
102	Mulhern D (2012) CST Curation Set: 13939; Year: 2012; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY] Curated Info
103	Singh AM, et al. (2012) Signaling network crosstalk in human pluripotent cells: a Smad2/3-regulated switch that controls the balance between self-renewal and differentiation. Cell Stem Cell 10, 312-26 22385658 Curated Info
104	Gupta M, et al. (2012) Dual mTORC1/mTORC2 inhibition diminishes Akt activation and induces Puma-dependent apoptosis in lymphoid malignancies. Blood 119, 476-87 22080480 Curated Info
105	Zheng Y, Asara JM, Tyner AL (2012) Protein-tyrosine kinase 6 promotes peripheral adhesion complex formation and cell migration by phosphorylating p130 CRK-associated substrate. J Biol Chem 287, 148-58 22084245 Curated Info
106	Wang S, et al. (2012) Extensive Crosstalk between O-GlcNAcylation and Phosphorylation Regulates Akt Signaling. PLoS One 7, e37427 22629392 Curated Info
107	Rikova K (2011) CST Curation Set: 13129; Year: 2011; Biosample/Treatment: cell line, MGH-7/unknown; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY]) Curated Info
108	Rikova K (2011) CST Curation Set: 13131; Year: 2011; Biosample/Treatment: cell line, MGH-9/unknown; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY]) Curated Info
109	Tsai YM, et al. (2011) Glabridin inhibits migration, invasion, and angiogenesis of human non-small cell lung cancer A549 cells by inhibiting the FAK/rho signaling pathway. Integr Cancer Ther 10, 341-9 21059620 Curated Info
110	Liu J, et al. (2011) PHLPP-mediated dephosphorylation of S6K1 inhibits protein translation and cell growth. Mol Cell Biol 31, 4917-27 21986499 Curated Info
111	Chen CH, Sarbassov dos D (2011) The mTOR (mammalian target of rapamycin) kinase maintains integrity of mTOR complex 2. J Biol Chem 286, 40386-94 21965657 Curated Info
112	Warfel NA, Niederst M, Newton AC (2011) Disruption of the interface between the pleckstrin homology (PH) and kinase domains of Akt protein is sufficient for hydrophobic motif site phosphorylation in the absence of mTORC2. J Biol Chem 286, 39122-9 21908613 Curated Info
113	Lu Y, et al. (2011) Kinome siRNA-phosphoproteomic screen identifies networks regulating AKT signaling. Oncogene 30, 4567-77 21666717 Curated Info
114	Hiraoka D, Okumura E, Kishimoto T (2011) Turn motif phosphorylation negatively regulates activation loop phosphorylation in Akt. Oncogene 30, 4487-97 21577208 Curated Info
115	Yuan J, et al. (2011) PF-04691502, a potent and selective oral inhibitor of PI3K and mTOR kinases with antitumor activity. Mol Cancer Ther 10, 2189-99 21750219 Curated Info
116	Su CH, et al. (2011) Akt phosphorylation at Thr308 and Ser473 is required for CHIP-mediated ubiquitination of the kinase. Cell Signal 23, 1824-30 21767636 Curated Info
117	Lodeiro M, et al. (2011) The SHP-1 protein tyrosine phosphatase negatively modulates Akt signaling in the ghrelin/GHSR1a system. Mol Biol Cell 22, 4182-91 21900501 Curated Info
118	Guo JP, Coppola D, Cheng JQ (2011) IKBKE protein activates Akt independent of phosphatidylinositol 3-kinase/PDK1/mTORC2 and the pleckstrin homology domain to sustain malignant transformation. J Biol Chem 286, 37389-98 21908616 Curated Info
119	Xiao L, et al. (2011) KIBRA Protein Phosphorylation Is Regulated by Mitotic Kinase Aurora and Protein Phosphatase 1. J Biol Chem 286, 36304-15 21878642 Curated Info
120	Pierre F, et al. (2011) Pre-clinical characterization of CX-4945, a potent and selective small molecule inhibitor of CK2 for the treatment of cancer. Mol Cell Biochem 356, 37-43 21755459 Curated Info
121	Roy D, Dittmer DP (2011) Phosphatase and tensin homolog on chromosome 10 is phosphorylated in primary effusion lymphoma and Kaposi's sarcoma. Am J Pathol 179, 2108-19 21819957 Curated Info
122	Haque A, et al. (2011) Conformation-sensing antibodies stabilize the oxidized form of PTP1B and inhibit its phosphatase activity. Cell 147, 185-98 21962515 Curated Info
123	Ohta E, Kawakami F, Kubo M, Obata F (2011) LRRK2 directly phosphorylates Akt1 as a possible physiological substrate: impairment of the kinase activity by Parkinson's disease-associated mutations. FEBS Lett 585, 2165-70 21658387 Curated Info
124	Guo A (2011) CST Curation Set: 11885; Year: 2011; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]P Curated Info
125	Guo A (2011) CST Curation Set: 11890; Year: 2011; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY] Curated Info
126	Guo A (2011) CST Curation Set: 11891; Year: 2011; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY] Curated Info
127	Guo A (2011) CST Curation Set: 11892; Year: 2011; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY] Curated Info
128	Wang H, et al. (2011) Convergence of the mammalian target of rapamycin complex 1- and glycogen synthase kinase 3-β-signaling pathways regulates the innate inflammatory response. J Immunol 186, 5217-26 21422248 Curated Info
129	Kwiatkowska A, et al. (2011) Downregulation of Akt and FAK phosphorylation reduces invasion of glioblastoma cells by impairment of MT1-MMP shuttling to lamellipodia and downregulates MMPs expression. Biochim Biophys Acta 1813, 655-67 21276823 Curated Info
130	Xie X, et al. (2011) IkappaB kinase epsilon and TANK-binding kinase 1 activate AKT by direct phosphorylation. Proc Natl Acad Sci U S A 108, 6474-9 21464307 Curated Info
131	Saci A, Cantley LC, Carpenter CL (2011) Rac1 regulates the activity of mTORC1 and mTORC2 and controls cellular size. Mol Cell 42, 50-61 21474067 Curated Info
132	Korolchuk VI, et al. (2011) Lysosomal positioning coordinates cellular nutrient responses. Nat Cell Biol 13, 453-60 21394080 Curated Info
133	Murata H, et al. (2011) A new cytosolic pathway from a Parkinson disease-associated kinase, BRPK/PINK1: activation of AKT via mTORC2. J Biol Chem 286, 7182-9 21177249 Curated Info
134	Nagashima K, et al. (2011) Genetic and pharmacological inhibition of PDK1 in cancer cells: characterization of a selective allosteric kinase inhibitor. J Biol Chem 286, 6433-48 21118801 Curated Info
135	Ou YH, et al. (2011) TBK1 Directly Engages Akt/PKB Survival Signaling to Support Oncogenic Transformation. Mol Cell 41, 458-70 21329883 Curated Info
136	Jensen J, et al. (2011) Effects of adrenaline on whole-body glucose metabolism and insulin-mediated regulation of glycogen synthase and PKB phosphorylation in human skeletal muscle. Metabolism 60, 215-26 20153492 Curated Info
137	Frederick MJ, et al. (2011) Phosphoproteomic analysis of signaling pathways in head and neck squamous cell carcinoma patient samples. Am J Pathol 178, 548-71 21281788 Curated Info
138	Chandarlapaty S, et al. (2011) AKT inhibition relieves feedback suppression of receptor tyrosine kinase expression and activity. Cancer Cell 19, 58-71 21215704 Curated Info
139	Vind BF, et al. (2011) Impaired insulin-induced site-specific phosphorylation of TBC1 domain family, member 4 (TBC1D4) in skeletal muscle of type 2 diabetes patients is restored by endurance exercise-training. Diabetologia 54, 157-67 20938636 Curated Info
140	Yang NY, et al. (2011) Crosstalk of the EphA2 receptor with a serine/threonine phosphatase suppresses the Akt-mTORC1 pathway in cancer cells. Cell Signal 23, 201-12 20837138 Curated Info
141	Yung HW, Charnock-Jones DS, Burton GJ (2011) Regulation of AKT phosphorylation at Ser473 and Thr308 by endoplasmic reticulum stress modulates substrate specificity in a severity dependent manner. PLoS One 6, e17894 21445305 Curated Info
142	Shibata MA, et al. (2011) α-Mangostin extracted from the pericarp of the mangosteen (Garcinia mangostana Linn) reduces tumor growth and lymph node metastasis in an immunocompetent xenograft model of metastatic mammary cancer carrying a p53 mutation. BMC Med 9, 69 21639868 Curated Info
143	Paweletz CP, et al. (2011) Identification of direct target engagement biomarkers for kinase-targeted therapeutics. PLoS One 6, e26459 22039492 Curated Info
144	Sundaresan NR, et al. (2011) The deacetylase SIRT1 promotes membrane localization and activation of Akt and PDK1 during tumorigenesis and cardiac hypertrophy. Sci Signal 4, ra46 21775285 Curated Info
145	Yang S, Xiao X, Meng X, Leslie KK (2011) A mechanism for synergy with combined mTOR and PI3 kinase inhibitors. PLoS One 6, e26343 22039466 Curated Info
146	Siddiqui-Jain A, et al. (2010) CX-4945, an orally bioavailable selective inhibitor of protein kinase CK2, inhibits prosurvival and angiogenic signaling and exhibits antitumor efficacy. Cancer Res 70, 10288-98 21159648 Curated Info
147	Hoang B, et al. (2010) Targeting TORC2 in multiple myeloma with a new mTOR kinase inhibitor. Blood 116, 4560-8 20686120 Curated Info
148	Xiao L, et al. (2010) Protein phosphatase-1 regulates Akt1 signal transduction pathway to control gene expression, cell survival and differentiation. Cell Death Differ 17, 1448-62 20186153 Curated Info
149	Shen X, Xi G, Radhakrishnan Y, Clemmons DR (2010) PDK1 recruitment to the SHPS-1 signaling complex enhances insulin-like growth factor-i-stimulated AKT activation and vascular smooth muscle cell survival. J Biol Chem 285, 29416-24 20643654 Curated Info
150	Zheng Y, et al. (2010) Protein tyrosine kinase 6 directly phosphorylates AKT and promotes AKT activation in response to epidermal growth factor. Mol Cell Biol 30, 4280-92 20606012 Curated Info
151	Qiang L, Banks AS, Accili D (2010) Uncoupling of acetylation from phosphorylation regulates FoxO1 function independent of its subcellular localization. J Biol Chem 285, 27396-401 20519497 Curated Info
152	Finnegan S, Mackey AM, Cotter TG (2010) A stress survival response in retinal cells mediated through inhibition of the serine/threonine phosphatase PP2A. Eur J Neurosci 32, 322-34 20636478 Curated Info
153	Bunkholt Elstrand M, et al. (2010) Mammalian target of rapamycin is a biomarker of poor survival in metastatic serous ovarian carcinoma. Hum Pathol 41, 794-804 20153512 Curated Info
154	Banerjee A, et al. (2010) Hepatitis C virus differentially modulates activation of forkhead transcription factors and insulin-induced metabolic gene expression. J Virol 84, 5936-46 20357092 Curated Info
155	Carnevalli LS, et al. (2010) S6K1 plays a critical role in early adipocyte differentiation. Dev Cell 18, 763-74 20493810 Curated Info
156	Kilili GK, Kyriakis JM (2010) Mammalian Ste20-like kinase (Mst2) indirectly supports Raf-1/ERK pathway activity via maintenance of protein phosphatase-2A catalytic subunit levels and consequent suppression of inhibitory Raf-1 phosphorylation. J Biol Chem 285, 15076-87 20212043 Curated Info
157	Chen CC, et al. (2010) FoxOs inhibit mTORC1 and activate Akt by inducing the expression of Sestrin3 and Rictor. Dev Cell 18, 592-604 20412774 Curated Info
158	Calay D, et al. (2010) Inhibition of Akt signaling by exclusion from lipid rafts in normal and transformed epidermal keratinocytes. J Invest Dermatol 130, 1136-45 20054340 Curated Info
159	Mallon R, et al. (2010) Antitumor efficacy profile of PKI-402, a dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor. Mol Cancer Ther 9, 976-84 20371716 Curated Info
160	Nava P, et al. (2010) Interferon-gamma regulates intestinal epithelial homeostasis through converging beta-catenin signaling pathways. Immunity 32, 392-402 20303298 Curated Info
161	Bidinosti M, et al. (2010) Postnatal deamidation of 4E-BP2 in brain enhances its association with raptor and alters kinetics of excitatory synaptic transmission. Mol Cell 37, 797-808 20347422 Curated Info
162	Sheng Q, et al. (2010) An activated ErbB3/NRG1 autocrine loop supports in vivo proliferation in ovarian cancer cells. Cancer Cell 17, 298-310 20227043 Curated Info
163	Moritz A (2010) CST Curation Set: 9280; Year: 2010; Biosample/Treatment: cell line, MKN-45/DMSO &'\|\|' Su11274; Disease: gastric carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY]) Curated Info
164	Moritz A (2010) CST Curation Set: 9235; Year: 2010; Biosample/Treatment: cell line, MKN-45/calyculin_A & pervanadate; Disease: gastric carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY]) Curated Info
165	Moritz A (2010) CST Curation Set: 9241; Year: 2010; Biosample/Treatment: cell line, NCI-H1703/untreated; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY]) Curated Info
166	Singh A, et al. (2010) Protein phosphatase 2A reactivates FOXO3a through a dynamic interplay with 14-3-3 and AKT. Mol Biol Cell 21, 1140-52 20110348 Curated Info
167	Alberobello AT, et al. (2010) Selective disruption of insulin-like growth factor-1 (IGF-1) signaling via phosphoinositide-dependent kinase-1 prevents the protective effect of IGF-1 on human cancer cell death. J Biol Chem 285, 6563-72 20044479 Curated Info
168	Moritz A (2010) CST Curation Set: 8838; Year: 2010; Biosample/Treatment: cell line, Jurkat/pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991 Curated Info
169	Zhao Y, et al. (2010) Identification and functional characterization of paxillin as a target of protein tyrosine phosphatase receptor T. Proc Natl Acad Sci U S A 107, 2592-7 20133777 Curated Info
170	Saavedra A, et al. (2010) PH domain leucine-rich repeat protein phosphatase 1 contributes to maintain the activation of the PI3K/Akt pro-survival pathway in Huntington's disease striatum. Cell Death Differ 17, 324-35 19745829 Curated Info
171	Seong HA, Jung H, Ichijo H, Ha H (2010) Reciprocal negative regulation of PDK1 and ASK1 signaling by direct interaction and phosphorylation. J Biol Chem 285, 2397-414 19920149 Curated Info
172	Moritz A (2010) CST Curation Set: 8865; Year: 2010; Biosample/Treatment: cell line, Jurkat/pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991 Curated Info
173	Chresta CM, et al. (2010) AZD8055 is a potent, selective, and orally bioavailable ATP-competitive mammalian target of rapamycin kinase inhibitor with in vitro and in vivo antitumor activity. Cancer Res 70, 288-98 20028854 Curated Info
174	Eto I (2010) Upstream molecular signaling pathways of p27(Kip1) expression: Effects of 4-hydroxytamoxifen, dexamethasone, and retinoic acids. Cancer Cell Int 10, 3 20170512 Curated Info
175	De Toni-Costes F, et al. (2010) A New alpha5beta1 integrin-dependent survival pathway through GSK3beta activation in leukemic cells. PLoS One 5, e9807 20352103 Curated Info
176	Gu M, et al. (2009) Inositol hexaphosphate suppresses growth and induces apoptosis in prostate carcinoma cells in culture and nude mouse xenograft: PI3K-Akt pathway as potential target. Cancer Res 69, 9465-72 19920184 Curated Info
177	Davies MA, et al. (2009) Integrated Molecular and Clinical Analysis of AKT Activation in Metastatic Melanoma. Clin Cancer Res 15, 7538-7546 19996208 Curated Info
178	Bai D, Ueno L, Vogt PK (2009) Akt-mediated regulation of NFkappaB and the essentialness of NFkappaB for the oncogenicity of PI3K and Akt. Int J Cancer 125, 2863-70 19609947 Curated Info
179	Dong W, Albers JJ, Vuletic S (2009) Phospholipid transfer protein reduces phosphorylation of tau in human neuronal cells. J Neurosci Res 87, 3176-85 19472218 Curated Info
180	Yang WL, et al. (2009) The E3 ligase TRAF6 regulates Akt ubiquitination and activation. Science 325, 1134-8 19713527 Curated Info
181	Tzatsos A (2009) Raptor binds the SAIN (Shc and IRS-1 NPXY binding) domain of insulin receptor substrate-1 (IRS-1) and regulates the phosphorylation of IRS-1 at Ser-636/639 by mTOR. J Biol Chem 284, 22525-34 19561084 Curated Info
182	Zhou J (2009) CST Curation Set: 7592; Year: 2009; Biosample/Treatment: cell line, HeLa/untreated; Disease: cervical adenocarcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]P Curated Info
183	Zhou J (2009) CST Curation Set: 7591; Year: 2009; Biosample/Treatment: cell line, HeLa/untreated; Disease: cervical adenocarcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]P Curated Info
184	Miao H, et al. (2009) EphA2 mediates ligand-dependent inhibition and ligand-independent promotion of cell migration and invasion via a reciprocal regulatory loop with Akt. Cancer Cell 16, 9-20 19573808 Curated Info
185	Chiang MH, et al. (2009) Mechanism of Hypoxia-induced GCM1 Degradation: IMPLICATIONS FOR THE PATHOGENESIS OF PREECLAMPSIA. J Biol Chem 284, 17411-9 19416964 Curated Info
186	Kim KY, et al. (2009) Adiponectin-activated AMPK stimulates dephosphorylation of AKT through protein phosphatase 2A activation. Cancer Res 69, 4018-26 19366811 Curated Info
187	Yim EK, et al. (2009) Rak functions as a tumor suppressor by regulating PTEN protein stability and function. Cancer Cell 15, 304-14 19345329 Curated Info
188	Park J, et al. (2009) DNA-dependent protein kinase-mediated phosphorylation of protein kinase B requires a specific recognition sequence in the C-terminal hydrophobic motif. J Biol Chem 284, 6169-74 19144640 Curated Info
189	Feldman ME, et al. (2009) Active-site inhibitors of mTOR target rapamycin-resistant outputs of mTORC1 and mTORC2. PLoS Biol 7, e38 19209957 Curated Info
190	Kawase T, et al. (2009) PH domain-only protein PHLDA3 is a p53-regulated repressor of Akt. Cell 136, 535-50 19203586 Curated Info
191	Guertin DA, et al. (2009) mTOR complex 2 is required for the development of prostate cancer induced by Pten loss in mice. Cancer Cell 15, 148-59 19185849 Curated Info
192	Ihle NT, et al. (2009) Mutations in the phosphatidylinositol-3-kinase pathway predict for antitumor activity of the inhibitor PX-866 whereas oncogenic Ras is a dominant predictor for resistance. Cancer Res 69, 143-50 19117997 Curated Info
193	Chabot C, et al. (2009) New role for the protein tyrosine phosphatase DEP-1 in Akt activation and endothelial cell survival. Mol Cell Biol 29, 241-53 18936167 Curated Info
194	Chua BT, et al. (2009) Regulation of Akt(ser473) phosphorylation by Choline kinase in breast carcinoma cells. Mol Cancer 8, 131 20042122 Curated Info
195	Monje PV, Athauda G, Wood PM (2008) Protein kinase A-mediated gating of neuregulin-dependent ErbB2-ErbB3 activation underlies the synergistic action of cAMP on Schwann cell proliferation. J Biol Chem 283, 34087-100 18799465 Curated Info
196	Koomoa DL, et al. (2008) Ornithine decarboxylase inhibition by alpha-difluoromethylornithine activates opposing signaling pathways via phosphorylation of both Akt/protein kinase B and p27Kip1 in neuroblastoma. Cancer Res 68, 9825-31 19047162 Curated Info
197	Higuchi M, Onishi K, Kikuchi C, Gotoh Y (2008) Scaffolding function of PAK in the PDK1-Akt pathway. Nat Cell Biol 10, 1356-64 18931661 Curated Info
198	Lee SB, et al. (2008) Nuclear Akt interacts with B23/NPM and protects it from proteolytic cleavage, enhancing cell survival. Proc Natl Acad Sci U S A 105, 16584-9 18931307 Curated Info
199	Hu Z, Chen J, Wei Q, Xia Y (2008) Bidirectional actions of hydrogen peroxide on endothelial nitric-oxide synthase phosphorylation and function: co-commitment and interplay of Akt and AMPK. J Biol Chem 283, 25256-63 18617528 Curated Info
200	Brummer T, et al. (2008) Phosphorylation-dependent binding of 14-3-3 terminates signalling by the Gab2 docking protein. EMBO J 27, 2305-16 19172738 Curated Info
201	Kinoshita H, et al. (2008) Roles of phosphatidylinositol 3-kinase-Akt and NADPH oxidase in adenosine 5'-triphosphate-sensitive K+ channel function impaired by high glucose in the human artery. Hypertension 52, 507-13 18678787 Curated Info
202	Zunder ER, et al. (2008) Discovery of drug-resistant and drug-sensitizing mutations in the oncogenic PI3K isoform p110 alpha. Cancer Cell 14, 180-92 18691552 Curated Info
203	Austin RL, et al. (2008) siRNA-mediated reduction of inhibitor of nuclear factor-kappaB kinase prevents tumor necrosis factor-alpha-induced insulin resistance in human skeletal muscle. Diabetes 57, 2066-73 18443205 Curated Info
204	Deep G, Oberlies NH, Kroll DJ, Agarwal R (2008) Isosilybin B causes androgen receptor degradation in human prostate carcinoma cells via PI3K-Akt-Mdm2-mediated pathway. Oncogene 27, 3986-98 18332867 Curated Info
205	Hong F, et al. (2008) mTOR-raptor binds and activates SGK1 to regulate p27 phosphorylation. Mol Cell 30, 701-11 18570873 Curated Info
206	McDonald PC, et al. (2008) Rictor and integrin-linked kinase interact and regulate Akt phosphorylation and cancer cell survival. Cancer Res 68, 1618-24 18339839 Curated Info
207	Banerjee S, et al. (2008) Hepatitis C virus core protein upregulates serine phosphorylation of insulin receptor substrate-1 and impairs the downstream akt/protein kinase B signaling pathway for insulin resistance. J Virol 82, 2606-12 18160431 Curated Info
208	Jindra PT, Jin YP, Rozengurt E, Reed EF (2008) HLA class I antibody-mediated endothelial cell proliferation via the mTOR pathway. J Immunol 180, 2357-66 18250445 Curated Info
209	Dos Santos C, et al. (2008) A critical role for Lyn in acute myeloid leukemia. Blood 111, 2269-79 18056483 Curated Info
210	Harwood FC, Shu L, Houghton PJ (2008) mTORC1 signaling can regulate growth factor activation of p44/42 mitogen-activated protein kinases through protein phosphatase 2A. J Biol Chem 283, 2575-85 18056704 Curated Info
211	Vojtechová M, et al. (2008) Regulation of mTORC1 signaling by Src kinase activity is Akt1-independent in RSV-transformed cells. Neoplasia 10, 99-107 18283331 Curated Info
212	Kuo YC, et al. (2008) Regulation of phosphorylation of Thr-308 of Akt, cell proliferation, and survival by the B55alpha regulatory subunit targeting of the protein phosphatase 2A holoenzyme to Akt. J Biol Chem 283, 1882-92 18042541 Curated Info
213	Yang KJ, et al. (2008) Regulation of 3-phosphoinositide-dependent protein kinase-1 (PDK1) by Src involves tyrosine phosphorylation of PDK1 and Src homology 2 domain binding. J Biol Chem 283, 1480-91 18024423 Curated Info
214	Zhou J (2008) CST Curation Set: 3677; Year: 2008; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pTXR Antibodies Used to Purify Peptides prior to LCMS: Phospho-Threonine-X-Arginine Antibody Cat#: 2351, PTMScan(R) Phospho-Thr-X-Arg Motif (T*XR) Immunoaffinity Beads Cat#: 1988 Curated Info
215	Di Fulvio M, Frondorf K, Gomez-Cambronero J (2008) Mutation of Y179 on phospholipase D2 (PLD2) upregulates DNA synthesis in a PI3K-and Akt-dependent manner. Cell Signal 20, 176-85 18006275 Curated Info
216	Ananthanarayanan B, Fosbrink M, Rahdar M, Zhang J (2007) Live-cell molecular analysis of Akt activation reveals roles for activation loop phosphorylation. J Biol Chem 282, 36634-41 17928291 Curated Info
217	Djouder N, et al. (2007) S6K1-mediated disassembly of mitochondrial URI/PP1gamma complexes activates a negative feedback program that counters S6K1 survival signaling. Mol Cell 28, 28-40 17936702 Curated Info
218	Selvendiran K, et al. (2007) EF24 induces G2/M arrest and apoptosis in cisplatin-resistant human ovarian cancer cells by increasing PTEN expression. J Biol Chem 282, 28609-18 17684018 Curated Info
219	Cen L, et al. (2007) PDK-1/AKT pathway as a novel therapeutic target in rhabdomyosarcoma cells using OSU-03012 compound. Br J Cancer 97, 785-91 17848913 Curated Info
220	Khundmiri SJ, et al. (2007) Ouabain stimulates protein kinase B (Akt) phosphorylation in opossum kidney proximal tubule cells through an ERK-dependent pathway. Am J Physiol Cell Physiol 293, C1171-80 17634416 Curated Info
221	Han EK, et al. (2007) Akt inhibitor A-443654 induces rapid Akt Ser-473 phosphorylation independent of mTORC1 inhibition. Oncogene 26, 5655-61 17334390 Curated Info
222	Odriozola L, Singh G, Hoang T, Chan AM (2007) Regulation of PTEN activity by its carboxyl-terminal autoinhibitory domain. J Biol Chem 282, 23306-15 17565999 Curated Info
223	Tzatsos A, Tsichlis PN (2007) Energy depletion inhibits phosphatidylinositol 3-kinase/Akt signaling and induces apoptosis via AMP-activated protein kinase-dependent phosphorylation of IRS-1 at Ser-794. J Biol Chem 282, 18069-82 17459875 Curated Info
224	Burelout C, Naccache PH, Bourgoin SG (2007) Dissociation between the translocation and the activation of Akt in fMLP-stimulated human neutrophils--effect of prostaglandin E2. J Leukoc Biol 81, 1523-34 17339610 Curated Info
225	Yuan G, et al. (2007) Tissue kallikrein reverses insulin resistance and attenuates nephropathy in diabetic rats by activation of phosphatidylinositol 3-kinase/protein kinase B and adenosine 5'-monophosphate-activated protein kinase signaling pathways. Endocrinology 148, 2016-26 17272402 Curated Info
226	Lee SB, et al. (2007) ATG1, an autophagy regulator, inhibits cell growth by negatively regulating S6 kinase. EMBO Rep 8, 360-5 17347671 Curated Info
227	Brognard J, Sierecki E, Gao T, Newton AC (2007) PHLPP and a second isoform, PHLPP2, differentially attenuate the amplitude of Akt signaling by regulating distinct Akt isoforms. Mol Cell 25, 917-31 17386267 Curated Info
228	Wang C, et al. (2007) Adiponectin sensitizes insulin signaling by reducing p70 S6 kinase-mediated serine phosphorylation of IRS-1. J Biol Chem 282, 7991-6 17244624 Curated Info
229	Crellin NK, Garcia RV, Levings MK (2007) Altered activation of AKT is required for the suppressive function of human CD4+CD25+ T regulatory cells. Blood 109, 2014-22 17062729 Curated Info
230	Rocher G, Letourneux C, Lenormand P, Porteu F (2007) Inhibition of B56-containing protein phosphatase 2As by the early response gene IEX-1 leads to control of Akt activity. J Biol Chem 282, 5468-77 17200115 Curated Info
231	Lerea KM, Venjara AY, Olson SC, Kelly MR (2007) Threonine phosphorylation of integrin beta3 in calyculin A-treated platelets is selectively sensitive to 5'-iodotubercidin. Biochim Biophys Acta 1773, 185-91 17052767 Curated Info
232	Lessmann E, et al. (2007) Oxysterol-binding protein-related protein (ORP) 9 is a PDK-2 substrate and regulates Akt phosphorylation. Cell Signal 19, 384-92 16962287 Curated Info
233	Leslie NR, Yang X, Downes CP, Weijer CJ (2007) PtdIns(3,4,5)P(3)-dependent and -independent roles for PTEN in the control of cell migration. Curr Biol 17, 115-25 17240336 Curated Info
234	Opel D, et al. (2007) Activation of Akt predicts poor outcome in neuroblastoma. Cancer Res 67, 735-45 17234785 Curated Info
235	Zagórska A, et al. (2007) Regulation of activity and localization of the WNK1 protein kinase by hyperosmotic stress. J Cell Biol 176, 89-100 17190791 Curated Info
236	Edling CE, et al. (2007) Haematopoietic progenitor cells utilise conventional PKC to suppress PKB/Akt activity in response to c-Kit stimulation. Br J Haematol 136, 260-8 17156394 Curated Info
237	Choudhari SR, et al. (2007) Deactivation of Akt and STAT3 signaling promotes apoptosis, inhibits proliferation, and enhances the sensitivity of hepatocellular carcinoma cells to an anticancer agent, Atiprimod. Mol Cancer Ther 6, 112-21 17237271 Curated Info
238	Barragán M, et al. (2006) Regulation of Akt/PKB by phosphatidylinositol 3-kinase-dependent and -independent pathways in B-cell chronic lymphocytic leukemia cells: role of protein kinase C{beta}. J Leukoc Biol 80, 1473-9 16940331 Curated Info
239	Van Meter TE, Broaddus WC, Cash D, Fillmore H (2006) Cotreatment with a novel phosphoinositide analogue inhibitor and carmustine enhances chemotherapeutic efficacy by attenuating AKT activity in gliomas. Cancer 107, 2446-54 17041888 Curated Info
240	King TD, Gandy JC, Bijur GN (2006) The protein phosphatase-1/inhibitor-2 complex differentially regulates GSK3 dephosphorylation and increases sarcoplasmic/endoplasmic reticulum calcium ATPase 2 levels. Exp Cell Res 312, 3693-700 16987514 Curated Info
241	Rousseau S, et al. (2006) CXCL12 and C5a trigger cell migration via a PAK1/2-p38alpha MAPK-MAPKAP-K2-HSP27 pathway. Cell Signal 18, 1897-905 16574378 Curated Info
242	Sastry KS, Karpova Y, Kulik G (2006) Epidermal growth factor protects prostate cancer cells from apoptosis by inducing BAD phosphorylation via redundant signaling pathways. J Biol Chem 281, 27367-77 16847055 Curated Info
243	Wei Q, Xia Y (2006) Proteasome inhibition down-regulates endothelial nitric-oxide synthase phosphorylation and function. J Biol Chem 281, 21652-9 16737962 Curated Info
244	Jia W, et al. (2006) Delta9-tetrahydrocannabinol-induced apoptosis in Jurkat leukemia T cells is regulated by translocation of Bad to mitochondria. Mol Cancer Res 4, 549-62 16908594 Curated Info
245	Chao OS, Clément MV (2006) Epidermal growth factor and serum activate distinct pathways to inhibit the BH3 only protein BAD in prostate carcinoma LNCaP cells. Oncogene 25, 4458-69 16767165 Curated Info
246	Zhang XP, Hintze TH (2006) cAMP signal transduction induces eNOS activation by promoting PKB phosphorylation. Am J Physiol Heart Circ Physiol 290, H2376-84 16428343 Curated Info
247	Gandy JC, Rountree AE, Bijur GN (2006) Akt1 is dynamically modified with O-GlcNAc following treatments with PUGNAc and insulin-like growth factor-1. FEBS Lett 580, 3051-8 16684529 Curated Info
248	Tomita Y, et al. (2006) Prognostic significance of activated AKT expression in soft-tissue sarcoma. Clin Cancer Res 12, 3070-7 16707604 Curated Info
249	Zeng Z, et al. (2006) Simultaneous inhibition of PDK1/AKT and Fms-like tyrosine kinase 3 signaling by a small-molecule KP372-1 induces mitochondrial dysfunction and apoptosis in acute myelogenous leukemia. Cancer Res 66, 3737-46 16585200 Curated Info
250	Huang M, Kamasani U, Prendergast GC (2006) RhoB facilitates c-Myc turnover by supporting efficient nuclear accumulation of GSK-3. Oncogene 25, 1281-9 16247449 Curated Info
251	Edwards LA, et al. (2006) Combined inhibition of the phosphatidylinositol 3-kinase/Akt and Ras/mitogen-activated protein kinase pathways results in synergistic effects in glioblastoma cells. Mol Cancer Ther 5, 645-54 16546979 Curated Info
252	Wingate AD, Campbell DG, Peggie M, Arthur JS (2006) Nur77 is phosphorylated in cells by RSK in response to mitogenic stimulation. Biochem J 393, 715-24 16223362 Curated Info
253	Wu Y, et al. (2006) Delineating the mechanism by which selenium deactivates Akt in prostate cancer cells. Mol Cancer Ther 5, 246-52 16505097 Curated Info
254	Shao Z, et al. (2006) c-Jun N-terminal kinases mediate reactivation of Akt and cardiomyocyte survival after hypoxic injury in vitro and in vivo. Circ Res 98, 111-8 16306447 Curated Info
255	Dorai T, et al. (2005) The role of carbonic anhydrase IX overexpression in kidney cancer. Eur J Cancer 41, 2935-47 16310354 Curated Info
256	Pim D, Massimi P, Dilworth SM, Banks L (2005) Activation of the protein kinase B pathway by the HPV-16 E7 oncoprotein occurs through a mechanism involving interaction with PP2A. Oncogene 24, 7830-8 16044149 Curated Info
257	Jung HS, et al. (2005) Regulation of protein kinase B tyrosine phosphorylation by thyroid-specific oncogenic RET/PTC kinases. Mol Endocrinol 19, 2748-59 15994200 Curated Info
258	Xu BE, et al. (2005) WNK1 activates SGK1 by a phosphatidylinositol 3-kinase-dependent and non-catalytic mechanism. J Biol Chem 280, 34218-23 16081417 Curated Info
259	de Alvaro C, Martinez N, Rojas JM, Lorenzo M (2005) Sprouty-2 overexpression in C2C12 cells confers myogenic differentiation properties in the presence of FGF2. Mol Biol Cell 16, 4454-61 16000370 Curated Info
260	Tremblay F, et al. (2005) Overactivation of S6 kinase 1 as a cause of human insulin resistance during increased amino acid availability. Diabetes 54, 2674-84 16123357 Curated Info
261	Weigert C, et al. (2005) Interleukin-6 acts as insulin sensitizer on glycogen synthesis in human skeletal muscle cells by phosphorylation of Ser473 of Akt. Am J Physiol Endocrinol Metab 289, E251-7